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Abstract 
There are a growing body of evidences that the human gut microbiota is involved in the 
pathogenesis of inflammatory bowel diseases (IBD). Two mains forms exists, namely 
Crohn’s disease (CD) and Ulcerative Coilitis (UC). Although these knowledge are so far 
limited, a better understanding of the gut microbes and variations in health and disease can 
contribute to inflammatory bowel disease diagnotics. 
In this current project as reported, was designed to determine correlations between the 
composition of the gut microbiota and IBD in children (less than 18 years old) and thus 
evaluate potentials for early diagnostics. From a repertoire of faecal specimens from early 
diagnosed IBD (CD and UC) and non-IBD controls at Akershus University Hospital bio-
bank, 75 children samples were analysed utilising bacterial small subunit (SSU) rRNA as 
biomarkers. DNA from this samples were extracted and purified using the QIAGEN 
QIAamp® DNA Stool Kit. Using a combination of forward and reverse primers that 
generally target the conserved regions of 16S rRNA gene of multiple microorganisms, the 
amplicons were direct sequenced. The mixed pool of sequences were subjected to 
multivariate curve resolution with resulting five components matched by Ribosomal 
Database Project search to, Faecalibacterium, Dialister, Haemopilus, Enterobacteriaceae 
and Bacteroides as dominant phylotypes and corresponding frequencies in all samples were 
obtained. To isolate pure bacterial species within the cohort, MCR selected samples were 
cloned into plasmid vectors of competent E. coli cells (TOPO®TA Cloning Kit) and 
sequenced. The clone library revealed earlier enumerated bacterial species in IBD cases 
against controls in literature and as well as Haemophilus, a previously uncharacterised gut 
bacteria. Similary, the clone library sequences were subjected to the Genetic Analysis (GA) 
in house probe design programme with specific settings that would generally label targets, 
excluding non-targets at the set conditions were screened on the cohort samples 16S rRNA 
amplicons utilising the GA two step single nucleotide extension (SNE) novel probe 
technology. In addition to six probes being screen, a Universal probe was screened for 
normalisation. 
To establish correlation to disease, data generated from both multivariate resolution and 
probe screening was put through the SYSTAT binary logistic regression model. The MCR 
prediction showed Faecalibacterium and Enterococcus significantly correlating to disease, 
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IBD and UC respectively. However, the selective probes showed specificity to Dialister and 
Haemophilus clusters, correlating to UC and CD respectively and hence the diagnostic 
potentials proposed. 
The finding in this study may have wider implication for early IBD diagnostic if followed up 
with extensive validation. 
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1. Introduction 
1.1 Preamble 
The human gut microflora is thought to be implicated in health and disease. (Hanauer, 2006). 
Increasing evidence currently exists from different studies on the effect of the gut microbiota 
in the development of conditions such as obesity, inflammatory bowel diseases, intestinal 
cancers and atopic diseases. However, our basic understanding of any underlying dynamics 
and variations in the gut microbiota to the individuals health and disease are very limited. 
Exploring these experimental lines of thought, can contribute to diagnostics, health care and 
lower morbidity due to chronic disease such as in idiopathic inflammatory bowel disease 
(IBD). (Mai & Draganov, 2009; Reiff & Kelly, 2010) 
1.2 The Human gut microbiota 
From parturition the human body becomes host to colonisation of a vast array of microbes. 
The environmentally exposed surfaces such as the skin, mouth, gut and vagina generally 
harbour these foreign microorganisms. (Round & Mazmanian, 2009) They develop co-
dependently, consequently aiding the host with coding capacity and metabolic activities and 
often described with the term “superorganism” (Dethlefsen, McFall-Ngai, & Relman, 2007; 
Ley, Peterson, & Gordon, 2006; Mai & Draganov, 2009; Shanahan, 2009; Ventura et al., 
2009). The nutrient-rich human gut bears a bulk of the diverse bacterial colonisation, an 
understanding that has implication in diseases and management of human health. 
(Dethlefsen, et al., 2007; Ley, et al., 2006)  
A body of research alludes that the composition of the gut microbiota is a result of both 
selective pressure imposed by the host and modulated through competitions among 
constituent bacterial residents. (Shanahan, 2009; Ventura, et al., 2009) The human GIT being 
the primary site of interaction between host and bacterial species involves various 
associations according to roles and effects. The symbiotic interactions between the human 
gut and the bacterial load has been described as mutualistic, commensal or pathogenic 
associations. (Round & Mazmanian, 2009; Saarela, Lähteenmäki, Crittenden, Salminen, & 
Mattila-Sandholm, 2002; Shanahan, 2009; Ventura, et al., 2009) Within the human 
gastrointestinal tract (GIT), the identified microflora from culture-independent studies has 
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revealed well over 1000 phylotypes of about 7000 strains within 8 major phyla (Ventura, et 
al., 2009). 
The human gut microflora has been shown to be impacted on host nutrition, immune 
responses and pathogenic invasion (Skånseng, Kaldhusdal, & Rudi, 2006; Ventura, et al., 
2009) and eventually providing certain functions which humans cannot perform in 
accordance with its lineage (Freilich et al., 2010; Qin et al., 2010). To better undertand these 
impacts on the host, a good understanding of the microbiota may allude to these interaction. 
Hence, bacterial ecological community models of evolution enables predictions on the 
ability of microorganisms to inhabit its host. (Freilich, et al., 2010; Woese, 1987) No other is 
this understanding relevant than the impact the human gut microbiota exacts on the host 
processes which may underline it genes, cells and brains among others (Woese, 1987). 
1.3 Inflammatory Bowel Disease (IBD) 
Inflammatory bowel diseases are a group of conditions of inflammation affecting the 
intestine, colon or anywhere within the gastrointestinal tract. The incidence of IBD has been 
characterised by an intermittence of a set chronic inflammation of the gastrointestinal 
mucosa, from the mouth to the anus (Figure 1.3.1). (Braun & Wei, 2007; Kuehbacher et al., 
2008) IBD patients exhibit symptoms like abdominal pain, emesis, diarrhea, rectal bleeding, 
fever, weight loss, odema, fatigue, general discomfort (malaise) and may flare up (relapse) 
after symptoms free periods (remission) (Braus & Elliott, 2009; Reiff & Kelly, 2010; E F 
Stange et al., 2006).  
In addition to these symptoms, an exhibition of extra-intestinal inflammation in joints, eyes, 
skin, mouth and the liver could be further manifestation of IBD patients (Bouma & Strober, 
2003). This could be important in diagnosis which does not only cite manifestation of 
intestinal symptoms (Karlinger, Györke, Makö, Mester, & Tarján, 2000). 
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Figure 1.3.1: Anatomy of the GIT (a) and Illustrating inflammation of the bowel (b). IBD characterised by 
inflammation could in theory affect any portion of GIT. [Image Sources: 
http://www.nlm.nih.gov/medlineplus/ency/imagepages/19219.htm and 
http://www.riversideonline.com/health_reference/Test-Procedure/MY00138.cfm] 
The main forms of these set of diseases are Crohn’s disease (CD) and Ulcerative colitis 
(UC). They both often exhibit similar characteristics features, however, it is distingushable 
clinically in the localisation of histopathological inflammation by screening and endoscopic 
features (Figure 1.3.2) and as well as through a profile of familial aggregation. Typically, 
diffused mucosal inflammation in UC cases are manifested retrogradingly in the rectum 
(large bowel) as pseudopolyps and may extend the entire colon in severe cases while CD 
involves skip lesions anywhere within the GIT (upper region) but most common in the 
terminal ileum (Figure 1.3.1). (Braun & Wei, 2007; Braus & Elliott, 2009; Salzman & 
Bevins, 2008; Sokol, Lay, Seksik, & Tannock, 2008; Xavier & Podolsky, 2007) Each 
diagnosed case can also be graded according to extent and severity of diseases, such as the 
number of blood stools per day (Baumgart & Sandborn, 2007; E F Stange, et al., 2006; E. F. 
Stange et al., 2008). 
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Figure 1.3.2: A colonoscopic image illustrating a healthy (Normal) and diseased (Crohn’s) of the transverse 
colon. Diseased colon shows numerous and deep ulceration of colonic mucosa. (Baumgart & Sandborn, 2007) 
1.3.1 Epidemiology 
There remains epidemiological suggestions that IBD prevalence and risk occurs mostly in 
the industralised nations of the West; North America and Europe (Braun & Wei, 2007; Braus 
& Elliott, 2009) within a North-South slope (E F Stange, et al., 2006; E. F. Stange, et al., 
2008). Similarly, current studies are revealing a constant rise in the cases of IBD in the 
developing worlds especially in the industrially emerged Asia (Braun & Wei, 2007; Braus & 
Elliott, 2009; Xavier & Podolsky, 2007).  Nevertheless, most patients tend to live normal 
productive lifes (Hanauer, 2006).  
The onset of IBD tend to take place within the second and third decades of life (Xavier & 
Podolsky, 2007). Peaking firstly between 15 to 30 years, gradual decrease to remission and 
then slightly relapse in advanced ages, 50 to 70 years (Hanauer, 2006). However, about 5 
years ago the prevalence of IBD patients in the USA and Europe are estimated at 1.4 and 2.2 
million respectively (Braun & Wei, 2007; Braus & Elliott, 2009). There are generally no 
significant differences in IBD incidence in both male and females but there are slight 
inclination to CD in females ( from 1:1 to 1.8:1) and UC in males. (Hanauer, 2006; 
Karlinger, et al., 2000) 
1.3.2 Etiology   
Currently, the precise aetiology of IBD has not been completely elucidated. However, the 
pathophysiological observation from various experimental studies and also involving animal 
models, suggest a multifactorial interplay involving the enteric microbiota, host genetic 
factor and immune function and with environmental implications (Figure 1.3.3). (Braun & 
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Wei, 2007; Braus & Elliott, 2009; Reiff & Kelly, 2010; Salzman & Bevins, 2008) 
Conversely, lifestyle can also alter the risk of disease. For example, smoking has shown a 
positive correlation particularly in CD studies. (Braus & Elliott, 2009). In essence, within the 
past few years, five theories has been postulated in the etiology of IBD, even though they 
have not all as yet been completely proven. These enumerated are; the persistence of specific 
infection, dysbiosis in the beneficial and dentrimental gut commensal bacteria, defective 
mucosal barrier function and microbial clearance and aberrant immunoregulation. (Braun & 
Wei, 2007; Sartor, 2006)  
 
Figure 1.3.3: The interacting factors in the pathogenesis of IBD. There are mounting evidence that an interplay 
of this factors explains the incidences of the disease in relation to control subjects (Braun & Wei, 2007) 
It is believed that an interplay of the gut microorganisms, the host immune function and 
epithelial cells underlays an individuals susceptibility to IBD or not and by the modulation 
of both genetic and environmental factors (Braun & Wei, 2007; Braus & Elliott, 2009). 
1.3.2.1 Host Genetic Factors 
 
IBD (UC or CD) as a heterogenous diseases has been elucidated with a complex host genetic 
risk. It is envisaged that 50% of CD and 10% of UC cases are associated with genetic 
susceptibility (Braun & Wei, 2007). The most proxy evidence is in familial aggregation 
studies where, 75% patients have some first degree relatives incidence of inherited IBD. This 
seems to have a stronger penetrance in CD compared to UC (Xavier & Podolsky, 2007). 
(Braun & Wei, 2007; Braus & Elliott, 2009; Hanauer, 2006) IBD is not inherited by 
Mendelian trait (Hanauer, 2006), however, there are high rate concordance in monozygotic 
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twins. This is about 50% in CD but lower in UC and 18% than in dizygotic twins (Braus & 
Elliott, 2009). Lately, to highlight the genetic implication of IBD, specific genes correlating 
to the diseases have been identified (Braus & Elliott, 2009) 
Over the last few years, genome wide screenings of single nucleotide polymorphism (SNP) 
and candidate genes have revealed at least 30 loci (Braus & Elliott, 2009) that contribute to 
the risk of IBD, most especially in CD subjects (Braun & Wei, 2007; Braus & Elliott, 2009; 
Hanauer, 2006; Reiff & Kelly, 2010; Sartor, 2006; Xavier & Podolsky, 2007). Similarly, 
some CD loci have shown to also effect the risk of UC (Braus & Elliott, 2009).  
The probable most important gene so far identified on IBD-1 locus of chromosome 16 is 
NOD2/CARD15 (nucleotide-binding oligomerisation domain 2/caspase activation and 
recruitment domain 15). (Braun & Wei, 2007; Braus & Elliott, 2009) The product of this 
gene is a protein which encodes for an intracellular peptidoglycan receptor that activates 
CARD and nuclear factor (NF)-κB-dependent pathway of the innate immune cellular 
activation. This is important in host-bacteria recognition and clearance of bacteria, involving 
both proinflammatory and protective molecules. (Braun & Wei, 2007; Hanauer, 2006; 
Salzman & Bevins, 2008) As at now, three mutations, causing amino acid substitution has 
been discovered. (Sartor, 2006) Although, the biological effects of NOD2/CARD15 
mutations are still unclear, its receptors localised in monocytes and Paneth cells may be 
responsible for the production and secretion of defensin, an antimicrobial peptide. As such 
can be important in the host barrier defence as shown in knock out mouse experiments and 
the eventually impact on the gut bacterial load. (Salzman & Bevins, 2008) 
There seem to be a number of associated genes involved in the pathogenesis of IBD 
(Salzman & Bevins, 2008), however, defective NOD2/CARD15 genes have reported 
association to 17-27% of CD cases (Hanauer, 2006). 
1.3.2.2 Immunoregulation 
 
The immune reactivity of the gut mucosa to foreign agents implicated by genetic 
suscepitibility, is both local and systemic and humoral and cellular. (Xavier & Podolsky, 
2007) Dysregulation in maintaining intestinal homeostasis is a compelling evidence in the 
pathogenesis of IBD from human and animal studies (Round & Mazmanian, 2009; Xavier & 
Podolsky, 2007). Similarly, the protective resistance of the mucosal wall is weakened in 
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susceptible IBD individuals leading to elevated circulating macromolecular antigens 
(Karlinger, et al., 2000). 
As a theory, it is stipulated that normal gut flora (commensals), act in such a mechanism as 
to blocks proinflammatory genes that activates the NF-κB-dependent pathway and thus 
hinder the expression of the inflammatory adaptive immune response (Hanauer, 2006). 
Hence, in IBD this mechnaism has been lost through infection of pathogenic bacteria 
(Karlinger, et al., 2000) or alteration of “normal” bacterial function which eventually leads to 
chronic and destructive immune responses (Hanauer, 2006). Although, the excessive 
activation of adaptive immune response is directly implicated in tissue damages 
(inflammation) in IBD patients. The innate immunity is the driving proxy of the residents 
and recruited mucosal B and T cell population. (Xavier & Podolsky, 2007) Conversely, risk 
of CD has been elucidated by the identification of mutations in the autophagy-related gene 
ATG16L1. This leads to impaired innate immune defences by as yet unknown mechanisms. 
(Braus & Elliott, 2009) 
 
Figure 1.3.4: Mechanism by which Treg cells exerts gut immunological homeostasis. Proinflammatory 
cytokines are thought to be downregulated by inhibiting T regulatory cells by mechanisms not completely 
elucidated. (Round & Mazmanian, 2009)   
Within IBD adaptive immune system, immunomodulation comprises of the immunglobin A 
and G produced in the  mucosal B cells and the complex mixture of T cells lymphocytes; T 
helper 1 (TH1), T helper 2 (TH2) or T helper 17 (TH17) phenotypes (Xavier & Podolsky, 
2007) which produces proinflammatory cytokines; interleukin (IL), tumour necrosis factor 
(TNF) and interferon-γ (IFNγ) (Round & Mazmanian, 2009). A consensus from various 
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studies has indicated that CD is characterised by TH1 mediated inflammation responses, 
whereas UC exhibits TH2-like cytokine profiles (Braus & Elliott, 2009; Xavier & Podolsky, 
2007) From animal and human studies, evidence exists that suggests that Treg cells are 
implicated in regulating intestinal immunological balance in experimental UC. As shown 
with mechanism of action illustrated in  Figure 1.3.4, Bacteroides fragilis, is demonstrated 
to illicit mucosal protective action on proinflammatory signals from H. hepatcus on 
epithelial cells through the secretion of polysaccaride A (PSA) and presentation on MHC 
class II of CD4 T cells. (Round & Mazmanian, 2009; Xavier & Podolsky, 2007). 
In general, there seem to exists more convincing data in the immunological pathogenesis of 
CD while the role of antigens and antibodies in UC is yet to be determined (Karlinger, et al., 
2000). Furthermore, an over stimulation of the immune responses in susceptible individuals 
can also be attributed to IBD pathogenesis (Bouma & Strober, 2003). 
1.3.2.3 Environmental and Lifestyle Risk Factors 
 
As mentioned earlier, the higher prevalence of IBD in developed and industralised regions 
such as the Scandinavia, and the development of IBD by migrants from rare incidence 
regions gives weight to the theory of environmental influences in IBD development. Thus, 
IBD has be perceived with lower incidence in regions of poorer sanitation and hygiene. 
(Hanauer, 2006) Often hinging on ones socio-economic status, the contributing lifestyle 
environmental factors includes, diet, smoking, exposure to sunlight, sanitation, chemicals 
(industrial/drugs), and occupation. (Hanauer, 2006; Karlinger, et al., 2000) 
A link between dietary factors and diseases is thought to be implicated with the number of 
diseases appear in the GIT (Karlinger, et al., 2000). However, studies linking diet to IBD 
incidence are still inconclusive. (Hanauer, 2006) In an instance, a 3 to 4-fold greater risk has 
been projected in frequent consumers of fast-food, a suggestion that the westernised dietary 
intake of high fatty acids have been associated with the risk of IBD. Other food substances, 
alcohol and size of of particles in the gut content has been reported in persistent CD. 
(Karlinger, et al., 2000)  
The observation relating smoking and IBD are complex but a unique pathophysiological 
factor (Hanauer, 2006; Karlinger, et al., 2000) which may overide genetical factors 
(Hanauer, 2006). In UC from diverse geographical regions, smoking is shown to be rather 
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protective in a dose dependent manner (Hanauer, 2006) but has a negative influence 
(Karlinger, et al., 2000) on CD patients. Conversely, ex-smokers are even 1.7 times at risk of 
IBD compared to those who has never smoked and twice likely to require colon surgical 
procedure (Hanauer, 2006). 
1.4 Gut bacteria and IBD 
The diverse human gut microbiota contains about 10
14
 microbes of greater than 500 species. 
In the course of time, many different bacteria has been hypothesied as causative agents of 
IBD in addition to other etilogical agents (few enumerated earlier). This may be due to the 
resemblance of symptoms of IBD with certain bacteria infections, such as in the early 
symptoms of Yersinia infection that is similar to symptoms of CD (Karlinger, et al., 2000). 
This theory is been applied to experimental evaluation, especially with the advent of the 
robust metagenomic approach to enumerating previously un-cultivable gut bacteria. 
However, results has not been consistent in pinpointing a specific bacteria agent in IBD 
etiology. Nonetheless, in susceptible individuals, pathogenic or normally enteric bacteria 
may induce and perpetuate chronic gut mucosal inflammation. (Sartor, 1997) UC is not 
observed in mice studies within a germ free environments (Bouma & Strober, 2003), hence, 
the theory implicating the human gut microflora in IBD may be valid (Hanauer, 2006). 
Consistent with most metagenomic studies, in health, the human gut microbiota is dominated 
by the members of the Bacteriodetes and Firmicutes phyla (Ley, et al., 2006; Mai & 
Draganov, 2009) From various IBD studies, etilogically implicated bacteria include, 
Faecalibacterium prausnitzii exerting a positive impact, described as antiinflammatory, 
while Escherihia coli and Mycobacterium avium paratuberculosis (MAP) have a negative 
impact as potential IBD infectious agents (Mondot et al., 2011; Salzman & Bevins, 2008; 
Sokol, Lay, et al., 2008; Sokol et al., 2008; E F Stange, et al., 2006; E. F. Stange, et al., 
2008). These are mainly established from differences in gut bacterial composition in 
analysed feacal samples between observed IBD cases and healthy subjects (Mai & 
Draganov, 2009). 
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Figure 1.4.2: Model showing the schematic interaction between the host factors and the microbiota in disease 
(imbalance) and health (balanced). (Salzman & Bevins, 2008) 
Thus, the interactive relationship, symbiosis or pathogenic, between the host and the gut 
bacteria are shaped by selective pressures within the host (genetic) and competitive 
modulation of resident microbial community, of which net effect may have implications on 
the health of the host. (Ley, et al., 2006; Ventura, et al., 2009) Similarly, an imbalance in the 
composition of the commensals or beneficial (symbiotic) bacteria and pathogenic bacteria 
creates an abnormal host microbiota, which may lead to IBD diseased state in risk bearing 
individuals as illustrated in Figure 1.4.2. (Blaser & Falkow, 2009; Round & Mazmanian, 
2009; Salzman & Bevins, 2008; Turnbaugh et al., 2007)  
The gut dysbiosis observed could be an increase or a reduction in diversity of a group or 
specific bacteria.  However, a drawback in attributing microbiota composition to disease is 
that is not a concensus regarding the normal range of microbiota diversity on a population 
level to makes this conclusions (Mai & Draganov, 2009). 
1.5 Describing Microbial Diversity 
An understanding into the role of the human gut microbiota is impeded with our limited 
knowledge of the milieu, individuality and which are often too conceptualised. The 
functional elucidation of the numerous and incredibly complex human gut microbiota is 
quiet labourous, technically intensive and expensive. The inaccessibility of the gut means the 
faster, easily reproducible in vitro approaches forms the most palatable, comparable to in 
vivo strategies. Despite, it is difficult mimicking in vivo colonic conditions exactly. Culturing 
approaches has yielded limited success given that approximately 80% of the species residing 
in the human gut are un-culturable obligate anaerobes. (Brugère, Mihajlovski, Missaoui, & 
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Peyret, 2009; Kovatcheva-Datchary, Zoetendal, Venema, de Vos, & Smidt, 2009; Peterson, 
Frank, Pace, & Gordon, 2008; Reiff & Kelly, 2010)  
Conversely, culture-independent studies based on nucleic acid identification are breaking 
grounds in realising the impact of the gut microbiota on the host health. (Reiff & Kelly, 
2010) The current metagenomics approach has improved the technicality of isolating diverse 
bacteria in specific communities and thus present a phylogenetic picture of species richness. 
(Reiff & Kelly, 2010; Tuohy et al., 2009) However, as the traditional culture methods 
improve for previous uncultured bacteria (Peterson, et al., 2008), a blend of the both 
strategies may completely establish the physiology, functionality and abundance of the 
metabolic active human gut microbiota species and its impact on the host responses 
(Brugère, et al., 2009; Reiff & Kelly, 2010).  
In details, the gut microbial community can be enumerated by applying some of the high-
throughput nucleic acid-based strategies in PCR amplification and PCR-based analysis, 
cloning, and sequencing among others. (Brugère, et al., 2009; Leser et al., 2002; Nocker, 
Burr, & Camper, 2007) 
1.5.1 Molecular markers and Amplification  
Bacteria classification has basically been by the nucleic-acid identification using the small 
subunit (SSU) of ribosomes, particularly, the 16S rRNA gene (Brugère, et al., 2009), often 
termed as universal molecular chronometer (Woese, 1987), present in all cellular organisms. 
These genes are highly conserved and offers a quick and orderly way of identifying gut 
microbe phylogenetic diversity (phylotype) and variations in the sequences (Achtman & 
Wagner, 2008), probably down to the species level (Brugère, et al., 2009) and may reliably 
indicate relatedness in the absence of lateral gene transfer (Peterson, et al., 2008). Thus, 
microbial species maybe defined despite no acceptable consensus (Achtman & Wagner, 
2008; Peterson, et al., 2008) as strains with greater than between 97% to 99% 16S rRNA 
identity or more than 70% DNA-DNA hybridization (Achtman & Wagner, 2008; Brugère, et 
al., 2009; Peterson, et al., 2008) are classed as species. Furthermore, the conserved 16S 
rRNA regions are used in microbial studies as they are relatively small, approximately 1.5 
kb, and can easily be target amplified by polymerase chain reaction (PCR) with identified 
universal oligonucleotide primers within a sample pool of different microbes, even at minute 
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quantities (Peterson, et al., 2008) and also useful in oligonucleotide probe targets (Brugère, 
et al., 2009).  
This molecular tool has greatly advanced attempts to elucidate the proposed implication of 
microbial factor on IBD (Reiff & Kelly, 2010). 
1.5.2 PCR-Based Analysis 
PCR-based fingerprinting as a molecular in tool in microbial community identification has 
proved useful, providing an overview of the resident gut bacteria and monitor dynamics in 
richness (Tuohy, et al., 2009). However, apart from DNA extraction protocol bias that can be 
carried over (McOrist, Jackson, & Bird, 2002; Trosvik et al., 2007), PCR efficiency bias of 
mixed template differential amplification (Trosvik, et al., 2007) and at other downstream 
stages (Tuohy, et al., 2009), which may leads to relative under or over representation of gut 
microbiota taxon. If this bias are overcomed, its been an invaluable tool for microbial 
community profiling. (Brugère, et al., 2009)  
Based on similar techniques, one of most commonly used PCR-based analysis protocol are 
the denaturing-gradient gel electrophoresis (DGGE) and temperature-gradient gel 
electrophoresis (TGGE) and its derived variants. This method reveals profiles of differential 
separation, analysing the 16S rDNA amplicons by denaturing rate of dsDNA, DGGE or 
temperature-dependent migration rate, TGGE. It is rapid and cost effective and may expose 
temporal flunctuation within the gut microbiota (Alper et al, 2005) and impact of 
environmental consequences when optimized (Tuohy, et al., 2009). Furthermore, terminal-
restriction fragment-length polymorphism (T-RFLP) is another molecular technique for 
profiling microbial communities and has been applied in digestive environment to quantify 
gut microbial diversity based on terminal DNA fragments variants of known enzymes 
restriction sites of 16S rRNA gene using fluorescent labelled PCR primers (Brugère, et al., 
2009).  Similarly, the use of the automated ribosomal intergenic spacer analysis (ARISA), 
can discriminate closely related species using the 16S rDNA analysis. (Achtman & Wagner, 
2008; Nocker, et al., 2007) This uses the high heterogenic length and nucleotide sequences 
of the intergenic transcribed spacer (ITS) region between the 16S and 23S ribosomal genes. 
In this process of microbial community profiling, the fluorescently tagged PCR product is 
detected on a laser sensitive automated sequencing system. (Nocker, et al., 2007) 
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1.5.3 Cloning and Sequencing 
The cloning strategy is a step in the identification of gut bacterial species by sequencing. 
Clone libraries are generated from PCR products of bacterial 16S rRNA pool, sticky ends 
such as 3’A overhang, generated by Taq polymerase is ligated to an efficient vector as 
inserts (Nocker, et al., 2007). In this way, an inventory, proximate of the microbial diversity 
in a community can be achieved from the sequences clone library (Leser, et al., 2002; 
Nocker, et al., 2007). However, the cloning process can be tedious and time consuming but 
can be cost effective with advances in high-throughput sequencing.  
In the last two decades sequencing of conserved genes has been used in phylogenetic tree 
construction and comparative studies of the gut microbiota and as served as an alternative to 
some PCR-based analysis which can be quite laborous (Nocker, et al., 2007). Typically, the 
classical sanger sequencing based on the fluorescently labelled DNA chain-terminating 
dideoxynucleotide triphosphates (ddNTPs) on the single base resolution of  
electrophoretically separated deoxyribonucleotide triphosphate fragments, has been 
efficiently used to obtain DNA sequences. Unfortunately, its expensive and limiting in 
throughput. (Brugère, et al., 2009; Peterson, et al., 2008) 
The latest and future sequencing technologies are poised to circumvent this limitations and 
as now applied in metagenomic analysis. This includes, pyrosequencing and the 
improvement in 454 pyrosequencing, that relies on sequencing by synthesis, with the later 
using immobilised and amplified templates on aqueous oil emulsified beads which can 
generate up to 400 bases as opposed to 100 bases by the pioneering pyrosequencing. By this, 
sequences are detected using a chemiluminescence enzyme tracking of DNA polymerase 
synthesis activity in the release of pyrophosphate on nucleotide incorporation (Brugère, et 
al., 2009) Furthermore and among others, analysis involving sequence by hybridisation for 
genotyping that uses oligonucleotide arrays is the future of high throughput DNA 
sequencing as it excludes most repetitive sequences and can by-pass the cloning activity of 
bacterial 16S rDNA which can be efficient for DNA fragments that cannot be propagated in 
bacterial vectors. Although, sequencing by synthesis can also be applied on oligonucleotide 
arrays. (Brugère, et al., 2009)  
Capillary gel electropheresis has suitably been used in the detection and separation of as far 
a single nucleotide differences in DNA and genomic sequencing. This tool is attractive 
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compared to convectional gel electrophoresis as more than 600 nucleotides can be resolved 
in one automated run. This DNA analysis by sequencing technology is faster and efficiently 
resolves DNA fragments, utilising high voltages of between 10-30 kV in fused 10-100 μm 
diameter silica micro-capillaries and fixed to ultra-sensitive fluorescence or UV absorbance 
detectors. (Cohen et al., 1988; Swerdlow & Gesteland, 1990) 
1.5.4 Microarray 
The use of DNA microarray has been an effectively powerful experimental tool used to 
simultaneously monitor several thousands of genes, measuring abundance and diversity in a 
community and often optimised for gut microbiota in IBD diagnostics platforms (Brugère, et 
al., 2009; Kovatcheva-Datchary, et al., 2009). The microarray platform is designed with 
taxonomically differentiated specific DNA sequences labelled probes that will hybridise to 
target DNA fragments on especially planar glass surfaces. This can be sensitive to single 
nucleotide polymorphisms (SNP) on target species but cross-hybridisation can be an issue. 
However, it has been used to analyse relationships between healthy and diseased gut 
microbiota (Kovatcheva-Datchary, et al., 2009). Flow cytometry can also be used in the 
analysis of microbial community similar to the microarray principle above, its limiting on 
the number of phylotypes that can be sorted at the same time. Furthermore, microarray 
technology has been advanced in the implication of microbial metabolic activity in the gut 
disorders, using radioistope labelled DNA or RNA probes to provide phylogenetic 
information. (Brugère, et al., 2009; Kovatcheva-Datchary, et al., 2009) 
Although, microarray represents an excellent tool to analyse and expose potential diagnostic 
biomarkers, but for a larger clinical scale analysis, combining the FlowMetrix system from 
Luminex is thought to be simpler, flexible, cost effective and high-throughput for the 
validation of biomarkers. The Luminex can thus, screen upto a hundred different transcripts 
in many samples by a multiplex of ligation mediated amplification. (Peck et al., 2006; Sherry 
A, 2006) This xMAP® technology, is fully automated, lists its application within a variety 
such as measuring cytokines in serum, transcription factors in cell lysate, or detecting SNP 
(single nucleotide polymorphs) and has been applied to microbial detection even at low 
DNA concentrations and diversity studies (Sherry A, 2006). It performs discrete bioassay on 
the surface of microspheres,  which are colour coded beads of two flourescent dyes with 100 
different intensities for analyses. Multiple lasers, report by identifying the colourings on each 
individual microspheres  particles from reads on the compact analyser.  
 24 
1.5.5 Specimen materials for mining gut microbiota 
In IBD studies, at least 50% intestinal bacteria is contained in the faecal matter (stool) 
(Braun & Wei, 2007) and biopsis have provided the rich wealth of gut microbes for it 
characterisation. (Brugère, et al., 2009; Lepage et al., 2005) Nonetheless, bacterial 
composition in the various intestinal sections are not represented by faecal bacterial 
composition and neither does it represent mucosal bacterial composition. (Salzman & 
Bevins, 2008)  
1.5.6 Data and Statistical Analysis, Bioinformatic tools 
In the rapidly evolving knowledge into microbial ecology and microflora implication to host 
dysregulation, the large accumulation of molecular data in predicting diversity, abundance 
and novel microbial function requires a theory of predictive power that is of practical value. 
The value of this theory to the microbiologist will aid the interpretation, classification and 
prediction of richness as observed through experimental data. (Prosser et al., 2007) However, 
most important theories may have limited application to microorganism and especially the 
gut microflora (Achtman & Wagner, 2008; Prosser, et al., 2007) and may not be suitable for 
high-throughput application (Trosvik, et al., 2007). Exploring the usefulness of metagenomic 
approach to unraveling microbial communities, computational tools have thus been 
developed to streamline and distil interpretation of the numerous microbial data post 
sequencing (Kunin, Copeland, Lapidus, Mavromatis, & Hugenholtz, 2008; Peterson, et al., 
2008). With most of the culture-independent sequences utilising the SSU rRNA (I6S), the 
Ribosomal Database Project (RDP) analysis has been used for taxonomic visualisation and 
to link phylogeny. The RDP alignment strategy includes as at date, greater than a million 
quality-controlled bacterial and archaeal small-subunit 16S rRNA sequences. (Cole et al., 
2009) However, other databases such as greengenes also provide current and comprehensive 
16S rRNA gene sequence alignment for phylogeny browsing, blasting and probing (Brugère, 
et al., 2009) and can further assist the researcher in interpreting microarray results and 
annotating novel sequences. Recent advances in microbial bioinformatic tools has created 
the MEGAN, a BLAST that profiles community composition based on sequence similarities 
with the highest hit, assuming the nearest phylogentic match by the lowest common ancestor 
algorithm (Kunin, et al., 2008). 
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Statistical analysis of metagenomic data can be useful to extrapolate frequency dynamics in 
the structure of microbial communities as in higher organisms. This way, bias mainly from 
probe and clone library data sets in DNA sequence alignment and taxonomic inference 
maybe by-passed. (Knut Rudi et al., 2007; K. Rudi, Zimonja, Trosvik, & Næs, 2007) In the 
face of the large amount of data from microbial community studies, multivariate curve 
resolution (MCR) is a mathematical tool with the goal to expose the individual elements 
effects in a mixture of components. (Garrido, Rius, & Larrechi, 2008) In general, using 
multivariate statistics is a way of finding structure in a data with lots of variables in a 
condensed format. One of such application is the principal components analysis (PCA), 
which gives a small number of linearised combination of the variables in that data set that 
highlights the existing variations in the whole data frame. 
1.6 Potential of gut bacteria in IBD Diagnostics and Management 
Currently, there seem to be no single pathogenic marker for IBD and as such approach to 
diagnosis involves a combination of clinical presentations, biochemical features and  
pathological examinations (Baumgart & Sandborn, 2007). The two forms of IBD, UC and 
CD can thus be confirmed (Baumgart & Sandborn, 2007) or differentiately diagnosed by the 
evaluation of a combination of this features manifested, however, this can be sometimes not 
so distinctive (Hendrickson, Gokhale, & Cho, 2002). 
Presence of blood and mucus in stool are seen in intestinal clinical presentation, which 
seems to be diagnosed early in UC compared to CD because of gross blood in stool 
(Hendrickson, et al., 2002). The extent and severity of blood and frequency of stool can 
classify disease. Conversely, the presence of diarrhea with blood and mucus exclude the 
similar but different inflammatory bowel syndrome (IBS) in IBD diagnosis (Baumgart & 
Sandborn, 2007). Abdorminal pain are experienced and can intensify in UC during bowel 
emptying. Extent and localisation and progression of the pain can differiate CD from UC 
with pains in left lower quadrant extending to the entire colon in UC patients and right lower 
abdominal quadrant in CD suffers. (Hendrickson, et al., 2002) Partial or complete colonic 
obstruction, stenosis with anal fissures and fistulae is a more common manifestaiton in CD 
patients. Also, extraintestinal markers observed in IBD sufferers include fever, weight loss 
especial in CD, delayed growth and sexual maturation in children, ulcer, osteopenia and 
renal implications. (Baumgart & Sandborn, 2007; Nocker, et al., 2007) 
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Biochemical tests such as stool examination is very paramount to exluding enteric pathogens 
exhibiting similar IBD symptoms such as Salmonella, Shigella, Yersinia, E. coli, 
Mycobacterium tuberculosis among others but will persist despite applying normal 
treatments for such infections. This test can also be performed in events of relapse (E. F. 
Stange, et al., 2008). Serological test investigates full blood count, microlytic anaemia, 
leukocytosis and thrombocytosis and results may give an indication of IBD. Low iron levels 
and high liver enzymes are also observable as biochemical inflammatory marker, such as c-
reactive proteins (CRP) which are less in UC but seen in elevated levels in 90% of CD 
patients. Perinuclear anti-neutrophilic cytoplasmic antibody (P-ANCA) and anti-
Saccharomyces cerevisiae antibodies (ASCA) test are useful to support IBD diagnosis and 
ASCA was seen to be highly specific when it presented in 89 to 97% of children with CD. 
(Baumgart & Sandborn, 2007; Hendrickson, et al., 2002) Genetic marker test may also be 
performed, although not conclusive in UC, NOD2 mutations of particular phenotypes have 
been associated with CD susceptibility and screening. Elucidation of other implicated genes 
are in the horizon (E F Stange, et al., 2006; E. F. Stange, et al., 2008).  
The suggestion of IBD manifestation can be further established by endoscopic and radiologic 
evaluation. Endoscopy and biopsis can be particularly useful in differentiating between UC 
and CD, while equally useful in determining the extend of colonic involvement in CD 
sufferers, utilising barium enemas. (Hendrickson, et al., 2002) These diagnostic features 
show at least 50% sensitivity and specificity and are considered due to its moderate 
reproducibility (E F Stange, et al., 2006; E. F. Stange, et al., 2008). 
With advancing knowledge in the etiology and prognosis of IBD, management has been 
based on a concensus of suggestive therapies which are not essentially curative but to 
maintain remission and flare ups (Baumgart & Sandborn, 2007). IBD therapies has mainly 
been through drugs adminstration to induce or prolong remission, nutritional intervention to 
control the disease and finally surgery  for either or both of the types of disease, UC and CD.    
The choice of drug therapy is dependent on the severity of the symptoms and the site and 
degree of disease involvement. Conversely, adverse side effect may be inevitable with some 
of the medications. In mild UC cases, sulfasalazine alone or combination with topical 
medications is used but intolerable side effects in some patients are overcomed using the 
newer 5-aminosalicylic acid medications. In CD cases, corticosteroids are used in the short 
term due to undesirable side effects for therapy to induce remission and disease activity. 
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However, in  mild and moderate CD diseases, sulfasalazine is used to maintain remission 
induced by corticosteroids. Also in both diseases, immunosuppressive therapy are often 
administered using steroid free azathioprine or 6-mercaptopurine and for faster effects in 
achieving or prolonging remission. Similarly, antibiotics such as metronidazole and 
ciprofloxacin are administered to CD patients at least in the short term. (Baumgart & 
Sandborn, 2007; Hendrickson, et al., 2002) 
Biologically, due to implication of TNF-α in CD pathogenesis, infliximab, an infused 
monoclonal anti-TNF-α have been successful in inducing and maintaining remission in 48% 
of cases. Furthermore, thalidomide, despite its side effects are effective inhibitors of TNF-α. 
(Hendrickson, et al., 2002) 
Finally, surgery is used to treat patients with very severe cases of perforation, rectal 
bleeding, toxic megacolon and irresponsive to medical managements and in complications. 
(Hendrickson, et al., 2002)  
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1.7 Project Rationale and Aim 
Idiopathic IBD has posed a challenge for complete management. Human gut bacteria on the 
evidence of recent studies, have been implicated in the pathogenesis of the diseases. Thus, 
there is need for early diagnostics approaches, an important step in achieving needed 
therapy. However, this target has fallen short largely due to complexities of the gut 
microbiota and the applicable tools for the elucidation of highly un-culturable intestinal 
microbes. To completely understand the complex changes in the gut microbiota composition 
that may predispose inflammation or even promote health, theres need to pursue assay 
techniques that can unravel any link between the metabolic activities of the bacteria in the 
gastrointestinal tract and diversity.  
In this project, the aim was to determine correlations between the composition of the gut 
microbiota and IBD in children (<18 years olds) and evaluate potentials for diagnostics. The 
approach involved molecular techniques including, 
 Direct sequencing of purified and quantified pool of bacterial 16S rRNA gene from 
children stool samples  
 Screening which incorporates Genetic Analysis (GA) AS novel gut microbiota probe 
tool 
 Enumeration of bacterial diversity and phylogeny from generated clone library.  
This project in comparison to previous studies found in literature, seem to be one of its kind 
trying to extrapolate dynamics in gut microbiota residents in IBD subjects with greater than 
50 patients stool samples, early diagnosed and untreated cases. 
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1.7.1 Outline of the Project 
This project is a 60-credit work, constituting the MSc Thesis of the Hedmark University 
College Masters programme in Commercial and Applied Biotechnology, 2011. The project 
was involved a collaboration between Genetic Analysis AS (GA) and Akershus University 
Hospital (Ahus). With  a large bio-bank of faecal material at Ahus in the IBESEN II study, 
and  applying the GA novel gut probes screening technology this project was achieved.   
A flow scheme of how the outline of this project was achieved is shown below: 
 
Figure 1.7.1: Schematic outline of the project work. In achieving the aim of this project work, analysis 
involved purification, quantification and amplification of DNA from 75 children stool specimens. Identification 
of faecal  bacterial load was accessed by sequencing, multivariate curve resolution analysis, cloning and 
sequence bioinformatics analysis. Probe evaluation and screening of the amplified 16S rRNA gene and data 
subjected statistical analysis was essential to enumerate potential for IBD diagnostic.   
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2. Materials and Methods 
2.1 Samples Cohort (IBESEN II) 
A total of 75 children samples (<18 years old) stored at -80°C, were provided from 
diagnosed patients stool specimens. Samples were deposited from diagnosed, early 
inflammatory bowel disease (IBD) patients at Akershus University Hospital (Ahus), Oslo 
Norway. These were part of the Norwegian IBSEN II study. From these collections, 27 were 
diagnosed Crohn’s Disease (CD), 16 diagnosed Ulcerative Colitis (UC) and 30 samples were 
from diagnosed non-IBD subjects (control) and with 2 “unconfirmed” prognosis (IBDU). 
Full list included in Table 2.1.1A. 
IBD diagnosis criteria for patient specimen included in the IBSEN II cohort were, abdominal 
symptoms including diarrhea and/or blood in stool for more than 10 days, endoscopic or 
radiological examinations for signs of inflammation and histological signs of chronic 
inflammation.  
Subjects with pathogenic gut bacteria infection (except Mycobacterium avium), parasites, 
cysts and eggs were excluded from this cohort. Similarly, comorbid patients with cancer, 
haematological or hepatological disorders, significant cardiovascular, neurological and 
respiratory conditions were not included in these study. In addition, other chronic 
inflammation were exempted from this study in both disease and control subjects. 
Finally, IBD diagnosed patients were classified as CD, UC or IBDU based on satisfying the 
set criteria (Table 2.1.2A in Appendix).   
2.2 DNA Purification and Quantification 
Mechanical lysis was achieved as per Ahus DNA prep protocol. Samples were thawed from 
frozen, -80°C and a scalpel, 180 to 220 mg of stool in each 2 mL microcentrifuge tube. 
These were mechanically and vigorously lysed with 1.6 mL of ASL buffer (Qiagen, Hilden, 
Germany) for 2 minutes at 30 Hz using magnetic beads (Qiagen, Hilden, Germany) on 
Qiagen® TissueLyser (Qiagen, Hilden, Germany) and further lysis at 95°C for 5 minutes in 
a heating block. On slight cooling, tubes containing lysed samples were centrigude at 17 G 
for 15 seconds and again at 17 G maximum speed for 1 minute. To the 1.4 mL of pipetted 
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supernatant in a fresh 2 mL tubes, and inhibitorEX-tablets (Qiagen, Hilden, Germany) were 
added with 1 minute bench incubation and 3 minutes maximum speed centrifugation at 17 G. 
Final centrifugation at 17 G for 3 minutes was repeated with at least 600 µL of supernatant 
in a new 2 mL tube. 
Similarly, a final automated purification of the DNA from the 600 µL supernatant lysate 
were achieved using the QIAGEN kit (Qiagen, Hilden, Germany) on the QIAcube 
purifier(Qiagen, Hilden, Germany). These protocol were as described in the QIAamp® DNA 
Stool Handbook (the relevant protocol sheet on www.qiagen.com/MyQIAcube). The 
QIAcube purifier were preloaded with reagents; proteinase K, AL buffer, ethanol, AW1 and 
AW2 buffers and AE elution buffer. The run selection on the QiaCube were as programmed 
at Ahus for stool DNA extraction: (ON) > DNA > QIAmp DNA stool > Human stool > 
Human DNA analysis > Start. 
Determination of concentration, yield and purity of extracted bacteral DNA pool from stool 
samples were achieved using the Nanodrop spectrophotometer, calculating the ratios at 
Ab260/280. Similarly, DNA length was visualised through 1.5% (w/v) agarose gel 
electrophoresis, stained with ethidium bromide at 100 V for 30 minutes using 100 bp or 1 kb 
ladder  and 2 μL of purified DNA and 1 μL of loading buffer per well and ran on 1X TAE 
buffer. This conditions were used in subsequent gel electrophoresis analysis.  
The purified DNA eluates were all normalised to a final working concentration of 1 ng/μL 
for all subsequent assays and analysis. This was determined by a dilution series of; 1, 1/10; 
and 1/100 and PCR gel image strength empirically selected from stock DNA samples 
extracted; two of each strong, weak and moderate visualised gel bands by subsequent PCR 
(GeneAmp PCR Systems 9700, PE Applied Biosystemss, Norwalk, USA or AB Applied 
Biosystems 2720 Thermal Cycler, Singapore) amplification with primers and parameters as 
outlined below and analysis of the product on 1.5% (w/v) gel Red® stained agarose gel. 
2.3 Polymarese Chain Reaction (PCR) amplification of 16S rRNA 
Using a combination of forward; 5’-TCCTACGGGAGGCAGCAG-3’ (MangaF-1) and 
reverse; 5’-CGGTTACCTTGTTACGACTT-3’ (16S-UR) primers generally targeting the 
conserved 16S rRNA DNA regions of multiple microorganisms, approximately 1200 bp, 
was used in the amplification. The reaction mix on ice contained 1.25 U HotFirePol (Solis 
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Biodyne, Tartu, Estonia), 1XB2 buffer(Solis Biodyne, Tartu, Estonia), 2.5mM MgCl2 (Solis 
Biodyne, Tartu, Estonia); 200 μM dNTP (Thermo Fisher Scientific, Surrey,, UK); 0.2 μM 
each of forward [Mangala F-1] and reverse [16S-UR] primers to 1 µL of 5 to 100 ng/μL 
(w/v) DNA template to a final volume of 25 μL. The PCR thermocycler was programmed 
for initial denaturation at 95°C for 15 minutes, and with 30 cycles of denaturation at 95°C 
for 30 seconds, annealing for 30 seconds at 55°C, elongation for 1 minute 20 seconds at 
72°C and at the end a final elongation for 7 minutes at 72°C. 
For the PCR analysis of cloning transformants however, the forward and reverse, primers; 
5’-CGCCAGGGTTTTCCCAGTCACGACG-3’(HU) and 5’-
GCTTCCGGCTCGTATGTTGTGTGG-3’(HR) respectively were instead used to target 
specific regions of approximately 1400 bp of the 16S rRNA gene with the flanking regions 
on either side.   
Furthermore, PCR product were visualised on 1.5% agarose gels, prior to any further 
analysis and probably for confirmation of amplification.  
2.4 Sequencing 
In an attempt at determining the identity of the bacterial pool of the 16S rRNA gene by 
direct sequencing, the PCR product were firstly cleaned up of excess nucleotides. By treating 
with 3U Exonuclease I (ExoI) and 8U SAP, Shrimp Alkaline Phosphatase (usb Corp, OH, 
USA) at 37°C for 2 hours and inactivated at 80°C for 15 minutes.  
The ExoSAP treated PCR product were diluted 10X, 1 μL placed in each well and included 
with 0.32 μM each of 5’-[C X30]CGTATTACCGCGGCTGCTGGCAC-3’ (U515FC30) 
primers, 1X BigDye buffer and 1 μL BigDye v1.1, incorporation reaction to a 10 μL total 
volume. The PCR thermocyler was programmed at 25 cycles of denaturation at 96°C for 15 
seconds and annealing and elongation at 60°C for 4 minutes. Similar approach in sequencing 
the picked clones with insert used using the 16S rRNA specific primers, 0.32 μM of forward; 
5’-TCCTACGGGAGGCAGCAG-3’ (MangaF-1) and reverse; 5’-
CGGTTACCTTGTTACGACTT-3’ (16S-UR) primers instead.  
BigDye® Terminator v1.1 cycle sequencing Kit (AB Applied Biosystems, CA, USA) was 
added to above completed ExoSAP reaction, volume of 10 μL. According to manufacturer’s 
instruction this addition was a 55 μL mastermix of Xterminator which included 10 µL 
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Xterminator and 45 µL SAM. These were vortexed (IKA® MS 3 digital, USA) with shaking 
at room temperature for 30 minutes at 1500 rpm and centrifuged (IEC Centra CL3, USA) at 
1078 G for 2 minutes.  Sequences analysis was on the ABI Genetic Analyzer 3130xl 
sequencer with 36 cm capillary array containing optimized polymer 7 (POP-7, Applied 
Biosystems). Injection time was set at 6 seconds at 90°C. The sequences generated were 
based called by the Sequence Scanner Software v1.0 (Applied Biosystems) and used for 
further bioinformatic analysis. 
2.5 Cloning 
Using the MCR resolved sequence components, DNA pools were empirically selected for 
cloning from each component, 15 samples in total. Corresponding to 3 for each component  
and within each classification of UC, CD and Control.  
2.5.1 Transformation 
The experimental outline used in generating the clone libraries of pure bacteria from direct 
sequencing was as stipulated in the TOPO®TA Cloning Kit, Invitrogen 
(http://tools.invitrogen.com/content/sfs/manuals/topota_man.pdf). Transformations was 
achieved into the plasmid vector, One Shot® Competent Cells; Chemical or 
Electrocompetent  (E.coli). Fresh PCR products were generated for each cloning reaction as 
in PCR amplification of 16S rRNA stipulated earlier. TOPO®TA Cloning reaction, 6 µL 
comprising of 4 µL fresh PCR product; 1 µL Salt Solution (Chemical Cloning) or Dilute Salt 
Solution (Electroporation); 1 µL TOPO® vector were mixed gently and incubated for 30 
minutes at room temperature and placed on ice. For the transformation of the competent 
cells, 2 µL TOPO®TA Cloning reaction were inoculated into each frozen (-80°C) and ice-
thawed vial of competent cells with gently mixing. Incubation was at room temperature for 
30 minutes and 42°C water bath heat-shock for 30 seconds and speedly placed on ice 
chemically competent cells or pulsed twice in ice cooled electro-cuvettes on Electroporator 
2510 (Eppendorf, Nether-HLnz GmbH, USA) at 1250 V for electrocompetent cells. 
Transformed cells are place in 15 mL snap-cap “Falcon” tubes with 250 µL room 
temperature SOC medium and incubated (innova™4080 incubator shaker, New Brunswick 
Scientific Co. Inc, New Jersey, USA) at 37°C for 1 hour at 200 rpm. The resulting broth, 
20/40 μL was spread out on a 30 minutes pre-warmed 50 μg/mL kanamycin selective LB 
agar plate, pH 7.0; 1.0% Tryptone; 0.5% Yeast Extract and 1.0% Sodium Chloride (NaCl), 
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autoclaved at liquid cycle for 25 minutes at 121°C and cooled prior to pouring on 10 cm 
plates (30 – 50 mL) inverted and stored at + 4°C in the dark. The surface of the LB agar 
plate were tinted with 40 mg/mL X-gal in dimethylformamide (DMF) prior to pre-warming 
and plating of the transformed cells. 
The kanamycin selective LB agar plated transformed cells were incubated (Termaks 
TS4115, Bergen Norway) at 37°C for at least overnight and colonies, white or light blue (as 
positive transformants) were picked with looped plastic sticks and resuspended individually 
in 50 μL 1X TE buffer and lysed at 99°C for 5 minutes. The recovered supernatant, from 
4000 rpm 3 minutes centrifugation of lysate was stored and subjected to further analysis. 
Conversely, a transformation control reaction was included in the cloning strategy 
experiments in the first instance to establish efficiency. The was same as the strategy for 
cloning samples above, however, the pUC19 plasmid was used instead of TOPO® vector and 
the selective LB agar plate contained 100 μg/mL ampicillin. 
The analysis of the positive transformants was achieved by PCR and gel electrophoresis. The 
pure sequences were elucidated by sequencing from based called spectra. 
2.6 Probe Design 
Sequences that were devoid of chimeras from the clone library were trimmed to similar 
length within the conserved regions of the 16S rRNA gene to fit the Genetic Analysis (GA) 
in-house-developed PhyloMode programme used in the design and construction of the probe. 
Firstly, sequences were transformed into multimers (5mers), normalised and compressed into 
sequence related taxa clusterings plot by Principal Component Analysis (PCA). 
Subsequently, the PCA plots were exported as a “pcam” file and subjected to another GA in-
house TNTProbe programme that identifies probes statisfy the criteria for defined targets 
detection and non-targets exclusion based on combined criteria of hybridisation and labeling. 
All probes were designed with minimum Tm of 60°C by the nearest neighbor method for the 
target group, while the non-target should have a Tm of < 30°C, or the absence of a cytosine 
as the nucleotide adjacent to the 3’-end of the probe. All probes satisfying the criteria were 
identified and exported as “fastagr” and the potential cross-labeling or self-labeling probes 
were evaluated as allowed on the programme. The designed DNA probes will bind to 
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complementary 16S rRNA of peculiar bacterium or group of bacteria from purified and 
amplified 16S rRNA. 
2.7 Probe Evaluation/Screening (Capillary Gel Electrophoresis) 
The identified probes (biomers.net) were evaluated on selected samples from the clone 
library.  Using 2 target and 3 non-target each of 6 probe, on a 36cm 3130xl capillary array 
(Applied Biosystems) in the ABI Genetic Analyzer 3130xl sequencer (Applied Biosystems) 
containing optimzed polyer 7 (POP-7) with injection time set at 16 – 22 seconds and 
electrophoretic conditions, run-time 180 seconds at 15 KV, current 100 μA and 60°C run 
temperature. Finally, 7 probes which includes the Universal probe, were eventually screened 
on the 75 children normalised DNA samples, 1 ng/μL in this study.  
The evaluation and screening of the designed probe by capillary gel electrophoresis, started 
with prior flourecence end-labelling, on ice, of the specific DNA probes for detection. The 
end-labelling was achieved in the dark as far as possible by the patented GA “two step 
Single Nucleotide Extension (SNE)” reaction where the fluorescent dye TAMARA binds to 
ddCTP (5-proparglyamino-ddCTP-5/6 TAMARA). (Vebo et al., 2011) The reaction mix 
contained 0.25 U Hot Termipol DNA polymerase; 1X Hot Termipol buffer C; 4 mM MgCl2; 
0.4 μM  5-proparglyamino-ddCTP-5/6 TAMARA; 5 μL H2O; 0.1 μM of each designed DNA 
probe and 2 μL 10X diluted ExoSAP treated 16S rRNA PCR products (approximately < 1 
ng/μL) as earlier (direct sequencing). With reaction mix centrifuged at 3000 rpm for 1 
minute and loaded on the pre set PCR thermocycler parameters; initial denaturation step, 
95°C for 12 minutes; 5 cycles of 96°C for 20 seconds and 60°C for 30 seconds denaturation 
and annealing conditions respectively; and a final elongation step for 5 seconds at 60°C. 
In addition, at 37°C and 80°C for 1 hour and 15 minutes respectively in the PCR 
thermocycler, the end-labelled reaction mix was incubated with 1 μL SAP treatment, 
removing any residual nucleotides and phosphate groups from the 5’ end of the PCR 
amplified bacterial 16S rRNA gene. If not assayed immediately completed reaction mix was 
stored at 4° C for at least 24 hours or at -20°C for longer. 
The reaction mix for capillary gel electrophoresis was 0.5 μL LIZ 120 (Applied Biosystem); 
9 μL HiDi formamide and 1 μL SAP treated end-labeled product and incubated at 95°C for 5 
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minutes in the PCR thermocycler. The mix was centrifuged at 3000 rpm and loaded 
according to parameters previously used the sequencer earlier in the probe evaluation.  
Generated signal peaks were scruitinised, base-called in the Gene Mapper 4.0 programme 
and similarly transformed numerically into peak “heights” (PH) and “area” (PA) for further 
statistical analysis. On the Gene Mapper 4.0 programme >size manage editor (used to set the 
standard for the peaks generated) < display plots (displayed table of heights and area of 
peaks) 
Logistic Regression statistical analysis was performed on the SYSTAT programme using the 
PH and/or PA values obtained. 
2.8 Bioinformatics 
Forward and reverse sequence reaction results were assembled, aligned and trimmed for 
noise within the highly conserved region using the freely downloaded CLC Software from 
CLC bio A/S (http://www.clcbio.com/index.php?id=479) and/or the BioEdit Software 
(http://www.mbio.ncsu.edu/bioedit/bioedit.html).  
The 16S rRNA gene sequences were further identified using the Ribosomal Database Project 
classifier for assigning phylogenetically consistent higher-order bacterial taxonomy 
(http://rdp.cme.msu.edu/classifier/classifier.jsp). 
2.8.1 Chimeric Sequences 
Empirically selected “high-quality” assembled and aligned sequences were filtered of 
chimeric 16S rRNA with the chimeric slayer algorithm in mothur (http://www.mothur.org/) 
prior to further analysis. “High-quality” sequence are thus described as sequences with less 
mismatch in the forward and reverse sequences consensus assembly and appropriately not 
short length. The relevant commands were used in the chimera slayer on the Mothur 
programme and as kindly assisted by Trine Frisli (PhD staff at HiHm). 
Sequences in fasta format were uploaded onto the programme (Mothur). Details of complete 
commands used in this programme is as listed in the Appendix, Figure 2.8.1A. A summary 
of the input sequences was generated with a command. In the event of sequences with 
unexpected lengths, filtering was commanded. With appropriate commands, candidate and 
template (reference) files which have been uploaded are aligned and set to chimera removal 
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base on the chimera slayer algorithm. Finally, a summary of the identified unique sequences 
were commanded and a file name was created for the sequences in the collection.    
This was adopted from KE Ashelford et al. (2006). The sequences that was screened for 
chimera were transformed into programme appropriate fasta format. Reference sequences 
devoid of chimera, “The rRNA16S.gold.NAST_ALIGNED.fasta reference alignment  ” was 
used as standard and as stipulated in the mothur programme. 
2.9 Statistical Analysis (including MCR analysis) 
The large set of mixed sequences were kindly resolved by Professor Knut Rudi using the 
Multivariate Curve Resolution (MCR) analysis in an attempt as to expose and recover the 
pure components in the spectral of sequences. All the analyses of sequence spectra were 
performed using MATLAB
®
 R2010a software (The MathWorks Inc., Natick MA, USA), 
Statistical and Bioinformatics toolboxes for MATLAB
®
. For EFA, PCA and MCR analyses, 
PLS Toolbox v5.8 for MATLAB
®
 (Eigenvector Research Inc., USA) were used.  
Firstly, an alignment of all of the mixed sequences spectra were generated and repeated for 
pre-processing and normalisation taking only small portions of individual peaks in the 
spectra to avoid peak shifts due to differences in retention times. Performed PCA and/or 
EFA determined the number of significant components explaining the most variations in the 
data set. With the pre-determined component number setting, MCR was run on the aligned 
spectra. MCR output are the information on the relative amount of each components in the 
individual sample/sequence in the data set and the based called spectra information on each 
components. 
The detailed process and commands used in the resolution is as appended in Figure 2.9.1A 
(Appendix). 
2.9.1 Regression analysis 
In order to find any correlation in the data generated and disease diagnostics, regression 
analysis was performed. The was achieved using the SYSTAT Logistic Regression 
programme as per programme outlines (http://www.scientificcomputing.com/articles-DA-
SYSTAT-13-110310.aspx) as revelant to our large data set and mostly recommended for 
clinical sampling studies. Binary logistic regression analysis tool was used in modeling, for 
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its specificity in regression diagnostics of the categorical dependent variables of disease (UC 
[3] or CD [2]) or not diseased (Control [1]) against independent continunious variable of 
either the peak area (PA) or peak height (PH) as extrapolated from the electrophoregram 
from capillary gel electrophoresis sequencing. From the main menu of the SYSTAT 
window, an output (outcome) was achieved by selecting in this specific order: Analyse; 
Regression; Logistic; and Binary, and within the appearing “dialog box” selected from the 
preloaded variables data with default parameters except that the “constant” was unchecked in 
the analysis of the direct sequencing MCR values (AV_COMP x). 
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3. Results 
3.1 DNA Extraction/Purification 
 
Figure 3.1.1: Post isolation DNA quantification. With a 1 kb DNA gel size ladder, feacal bacterial DNA was 
visualised at >5 kb. The DNA band strength was varied and was thus graded as indicated, Strong, Moderate 
and Weak. Sheared or degraded products are shown in circled lane and graded similarly.      
DNA band visualised showed varying intensity and these strengths (Strong, Moderate or 
Weak) were noted as shown with images in Figure 4.1.1. The full list of all samples as 
graded are tabulated in Figure 3.1.1A (Appendix), DNA concentration and optical density 
(OD) ratio (Ab260/280) showed no trends with DNA gel strength and observed degradation 
products or sheared DNA as visibly very thick bands towards the end on gel lane. The OD 
ratio was not consistent within the reference range of ~1.8 (pure DNA) and ~2.0 (pure RNA) 
which could not be explained as spectrophotometric light interference from sheared DNA or 
degraded products. However, they were still acceptable for the amplified “housekeeping” 
gene, 16S rRNA analysis as seen in electrophoresis gels confirmation prior to further 
analysis (not shown). 
3.2 Direct Sequencing 
a.) Sequence quality 
The sequencing of the amplified bacterial 16S DNA pool of 75 childreen stool samples, 
overall produced nucleotides information of acceptable quality value. Specifically, sequence 
were qualifiied as saturated, strong, moderate, weak and poor, shown in Figure 3.2.1 with 
excerpts of electropherogram reads with grading in Table 4.2.1A, indicated that 60% and 
25.33% of the sequenced nucleotides were deemed good and moderately good respectively 
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for analysis, according to ABI Biosystems handbook. About 1% of the nucleotides signal 
strength was saturated. Conversely, 8% were poor while 4% of the raw signal reads showed 
no readable nucleotide information.  
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Figure 3.2.1: Sequence Electropherogram reads (excerpts) from the direct sequencing of the PCR amplified 
stool DNA by the automated ABI Genetic Analyzer 3130xl sequencer. Traces designated I, II, III, IV and V  
show grading of signal strength of the raw sequence quality as; Saturated (≥8000), Good (≥2000), Moderate 
(≥1000), Poor (≤1000) and Noise (No readable signals) respectively based on Raw trace (upper scan). 
b.) Application of the Sequences (mixed) to Multivariate Curve Resolution 
With no prior knowledge of the bacterial composition in each of the sampled pool of DNA 
sequenced, MCR treatment decomposed a concentration of 6 sequence components in the 
sequence spectral data. The Table 3.2.2 has enumerated the suggested MCR base called 
sequence components with the RDP search matches, Faecalibacterium, Dialister, 
Haemophilus, Enterobacteriaceae and Bacteroides as dominant within each pool scan. The 
base call of component 2 was a short read and thus was discarded as noise with no RDP 
sequence match revealed from search.  
Table 3.2.2: MCR components from mixed sequences of 75 children different samples. Sequence Match from 
RDP database indicates abundant bacteria group in the pool of diverse bacterial sequences. 
Components 
(match) 
Sequences 
Comp1 
(Faecalibacterium)  
AGCGTGTCCGATTTACTGGGTGTAAGGGAGCGCTAGCGGAGAGCAAGTTCGGAGTGAA
ATCCATGGGCTCAACCCATGGAARTGCTTTCAAACCTTGMTTTTCTTTGYTAGTGCAAAG
GTAAAGTCGGATRCCTGAGGTGGTACGGGTGGAATGCGTAATATTYGGAGGAACACCAT
GGCAAGGCGGTCRTACTGGGCACCAACTGACGRTGAGGCTCAA  
Comp2   
(Designated Noise)  
AGCTAGTATCCGGATTCTARTGGGTGTAAAGGGCGTAGCGGTTATCTAAAGGGCTTTT  
Comp3   
(Dialister)  
AGCGTTGTCCGGATTATTGGGCGTAAAGCGCGCGCAGGCGGCTTTCCRAAGTCCTCTCTT
AAAAGTGCGGGGCTTAACCCCMGYTG 
GGGYATGYAACCTGGYAAYCCTGGAGTATCGGAYAGYAAAGMGAGAATTCCATAGTGT
AGCGGTYAAATGCGTAAGATTAGGAAG 
AACACCGGTGGCGAAGGSGACTTTCTGGACAAAACTGACGCTGAGGCGCGAAA  
Comp4 (Haemophilus)  AGCGTTATTCGGAATAARTGGGCGTAAAGGGCACGCAGGCGGTGKCTTAAGTGAGGTGT
GAAAGCGCCCGGGCTTAACCTGGGAATMGCATTTCATACTGGGGTGCCGTAAMTACTTT
AGGGAGYGGTAYATATTCTCACGTMGTAGCGGTYAAWGTSCTTAAGTATGTGAAGYAA
TACCGAAGGCAGAAGSCARCCCTMGGAWTGTCACGTGACSRTCATGTGCAAA  
Comp5 
(Enterobacteriaceae)  
AGCGTTAATCGGAATTACTGGGCGTAAAGCGCACGCGGCGGTTTGTTAAGTCAGATGTG
AAATCCCCGGGCTCAACCTGGGAACTGCATCTGATACTGGCAAGCTTGAGTCTCGTAGA
GGGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGT
GGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAA  
Comp6 (Bacteroides)  ACGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGTGGARTTGTTAAGTCATGTATGT
GAAAGCTTTGCGGCTCAACCGTAAAATTGCATTTGAWACTGGAAGWCTTGAGTGCAGT
AGAGGRAGAGGCGGAATTCCTGGTGTAGCGGTGAAATGCTAATATCACGAAGAACATC
CGATGTGCGAAGGCGGCTTAGCTGGACTGTAACTGACYRTGAMGCTCGAAA  
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Consequently, the MCR technique recovered numerical data as average component 
frequency values for each of the sampled sequences. The highest component values within 
each sample DNA sequence formed the bases for the selection of DNA sample for cloning. 
In the bar chart, Figure 3.2.3, cloned selection is ploted and the overall data can be perused 
in the Appendix, Figure 3.3.3A. 
 
Figure 3.2.3: MCR data as used for clone library collection. Bar Chart value represents average frequency of 
each component (as colour codings) in the resolved mixed sequences. Within this selection, the most abundant 
(highest) MCR average component (1-6) value for each diagnosis (Control,CD and UC) was assumed for 
cloning [Samples 32, 86, 87, 111, 119, 172, 198, 1030, 5009, 6001, 6005, 6009, 6032, 6034 and 6036]. 
c.) Relating sequences to MCR data 
An overrepresentation of the Enterobacteriaceae (Comp5) was indicated in the mixed 
sequence-MCR component abundance analysis matrix (Figure 3.2.4) and closely followed in 
abundance was the Faecalibacterium (Comp1) and Bacteroides (Comp6) in the sampled 16S 
rRNA sequences. Haempohilus (Comp4) and Dialister (Comp3) with high intensity of blue 
suggest underrepresentation within the sampled sequence pool. In other words, samples 
cloned (as indicated with the arrows in Figure 3.2.4) were representative of the samples with 
relatively overrepresented components as to extrapolate any correlation with disease. 
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Figure 4.2.4: A permuted matrix relating the calculated MCR average component (Av. Comp 1, 3, 4, 5 and 6) 
abundance within each specimen faecal DNA sequenced. Selected samples that were cloned are indicated with 
the pointing arrow. Diagnosis represented for each sample; 1=Control, 2=CD; 3=UC and 4=IBDU. [Av. Comp 
ranges from 0.0 -2.0 with colour codes, Blue indicates underrepresentation of components, while red indicates 
an overrepresentation of components for each sampled DNA sequences.Conversely, colours inbetween a 
representative abundance of components].  
Also, as indicated in the permuted matrix (Figure 3.2.4), there seem a taxanomic relationship 
among the species communities in the DNA sequence pool except for two samples, one each 
of control and UC, with a different lineage from the rest. 
3.3 Cloning results 
Frequency of transformants with inserts analysed by colony PCR  as shown in gel picture of 
Figure 3.3.1, gave a 52.1% (100/192) for chemically transformed bacterial 16S rRNA 
fragments (~1400bp) and in most cases, incubation time of transformed fragments lasted 
several days to generate visible colonies. However, the greater efficiency of transformation 
was achieved by the electroporation protocol which raised frequency to 76% (513/675) from 
overnight incubation. 
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Figure 3.3.1: Colony PCR gel electrophoresis analysis of clone transformants. PCR product of picked clones 
(white or light blue), analysed by 1.5% agarose gel electrophoresis showed lanes with or without inserts of 
DNA fragment, transformed using TOPO® Vector in One Shot® Competent Cells (E. coli) by electroporation or 
chemical cloning. Frequency of positive transformant (clones with inserts) analysed was greater by 
electroporation as compared to chemical cloning.  
a.) Clone library 
From MCR data values as in excerpts ploted in the bar chart above, 15  16S DNA samples 
were selectively cloned, generating about 600 clone sequences. With 308 assembled 
(forward/reverse) sequences of appreciable quality, 283 sequence were devoid of chimeria 
from the chimera slayer algorithm and thus formed the clone library for any further analysis. 
As shown in the clone library is representative of human gut bacterial load.   
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Table 3.3.2: RDP 16S rRNA sequences matches summary for clone library sequence. Phylotype abundance 
given in brackets for each diagnosis. 
Domain  
(Control, CD, UC)  
Phylum  
(Control, CD, UC)  
Genus  
(Control, CD, UC)  
Bacteria (49, 112, 122)  Firmicutes (23, 59, 49)  Dialister (5, 1, 16)  
Enterococcus (0, 14, 0)  
Faecalibacterium (3, 1, 9)  
Lactobacillus (0, 1, 19)  
Subdoligranulum (2, 17, 3)  
Unclassified genus (3, 7, 8)  
Proteobacteria (20, 39, 48)  E.coli (20, 19, 23)  
Haemophilus (0, 16, 18)  
Unclassified Pasteurellaceae (0, 3,7)  
Bacteroidetes (6, 12, 24)  Bacteroides (2, 8, 22)  
Verrucomicrobia (0, 1, 0)  Akkermansia (0, 1, 0)  
TM7 (0, 1, 0)  unclassified  
 
An RDP search for sequence matches in the clone library, retrieved the listed phylum and 
genus in the Table 3.3.2 above with the complete list in Appendix (Table 3.3.2A). Sequences 
reads recovered from the sequenced clones suggest the Firmicutes and Proteobacteria were 
the most dominant phyla and with abundance within the diseased (CD or UC) category. 
However, there was also a shift in most phylotype abundance tendency within the Firmicutes 
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in CD cases (59) as opposed to UC cases (48) in Proteobacteria. In other words, the 
phylotypes that was determined to be increased in UC (Proteobacteria and Bacteroidetes) as 
compared greater CD phylotypes in Firmicutes. Bacteriodetes are also seen to be deplected 
in comparison to the Firmicutes and Proteobacteria groups. However, within each phylotype 
recovered, there were raised in the diseased category in comparison to the control group 
except for Verrucomicrobia and TM7.  
Haemophilus RDP matches from clone sequences was in the disease category, CD and UC, 
with almost same abundance 16 and 18 respectively and not at all from clone sequences in 
the control groups. This was noted with an interest as this has not been previously reported. 
b.) Phylogeny 
 
Figure 3.3.3: Phylogenetic tree from CLC genomic tool. A radial phylogram illustration of the taxanomic 
relationships of the clone library sequences (RDP match) of the 16S rRNA genes as a multiple tree drawn using 
the Dendroscope programme. Clone identity (e.g 6001.1) and diagnosis (Control,CD & UC) indicated with 
root/node distances along trees. Similarly, coloured bacteria species (Haemophilus, E. coli, Dialister, 
Faecalibacterium, Enterococcus, and Lactobacillus) indictate coverage within the tree of the six designed 
probes screened for any correlation to disease (IBD) diagnostics. 
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The dendrogram illustrated in Figure 3.3.3 is a representation of the phylogeny and diversity 
of bacterial sequences in the clone library of the samples selectively cloned in a cladistic 
tree. Basically, four different clusters of bacteria are represent from the sequence library. 
This includes the three phyla; gram positive Firmicutes (Subdoligranulum, 
Faecalibacterium, Clostridium, Ruminococcus, Dialister); facultative anaerobic species 
Proteobacteria (E.coli) and gram negative Bacteroidetes (Parabacteroides, Bacteroides) and 
the other groups includes TM7, a subgroup of gram-positive bacteria. 
From the clone library sequence matches, only Faecalibacterium and Dialister were 
matched in the MCR components resolved.   
3.4 Probe identification 
a.) PCA Clusters 
 
Figure 3.4.1: PCA plot indicating 16S rRNA sequence clusters for probe design. Targets (Haemophilus, top or 
Dialister, bottom) indicated in defined clusters (green) and excluded non-target (red). From a total of 303 
forward/reverse assembled 16S sequences clone libray of children gut bacteria, 282 chimera free sequences 
generated over 19 probes according to PCA clustering of related 16S sequences.  
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In the design of the probes, clustering of all the 283 clone library devoid of chimeras are as 
represented in the quadrants of the PCA plot in Figure 3.4.1. Within each window 
(PCA1,PCA2,PCA3….PCAx) as shown in the axis, probes sequences generated in the GA 
“in-house” TNTprobe programme revealed quite a lot of probe sequences, of which 19 
probes (list in Table 3.4.1A in the Appendix) were quality enough in theory, as verified by 
the programme the used to hybrise on targets and exclude non-target. In these windows, 
clusters reflected sequence similarities and probes identified sequences targets such Dialister 
and Haemphilus (indicated with circles in Figure 3.4.1) from the clone library sequences.   
b.) Probe Evaluation/Screening 
 
Figure 3.4.2: Signal reads from Probe Evaluation by capillary gel electrophoresis. Probe treated samples illicits 
hybridisation of target (A and D) sequences as peak (shown with pointing arrow) and excluded non-targets (B 
and C). However, a labeled peak in both targets and non-targets (C and D), eliminates P21 (Probe 21, targeting 
Faecalibacterium) in the above figure as a choice screening probe for all 16S rRNA sequence from the children 
samples. 
Probes evaluated that showed specificity were fit for screening on all PCR amplified 16S 
rRNA gene samples in this study. There were 6 probes screened as well the Universal probe 
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(Table 3.4.3). Probes that are labeled on its target as peaks as indicated with the pointing 
arrows in Figure 3.4.2 were deemed successful. Thus the size of the peak gave an indication 
of the abundance of the bacterial target that the probe labelled. The successfully labeled 
samples from the capillary gel electropherograms reads were extrapolated as “peak heights” 
(PA) (See Table 3.4.2A in Appendix) on the GeneMapper programme for statistical analysis.  
Table 3.4.3: List of Probes, sequences and the targeted bacterial in brackets. 
Probe # (Targets) Probe Sequences 
P_3 (E. coli)  GCCTCAAGGGCACAAC  
P_6 (Dialister) AAGAACTCCGCATTTCTGC  
P_8 (Faecalibacterium)  CGTAGTTAGCCGTCACTTC  
P_13 (Haemophilus)  TCGCTTCCCTCTGTATACG  
P_16 (Enterococcus)  CCCTCCAACACTTAGCA  
P_18 (Lactobacillus)  CCTGTTTGCTACCCATACTTT  
UNI01 (16S Universal)  CGTATTACCGCGGCTGCTGGCA  
 
3.5 Logistics Regression Analysis 
The “peak heights” numerical values earlier as extrapolated and analysed by SYSTAT 
binary logistics regression for its unique and linear output application in disease diagnostics. 
This exposed any implication of probes to diseases diagnostics in relation to the non-IBD 
control subjects. Similar analysis was performed with the MCR component frequency 
values.   
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a.) MCR data 
Table 3.5.1: Binary Logistic Regression analysis on MCR data. Significance (p <0.05) is highlighted ** in 
targets Enterobacteriaceae (UC) and Faecalibacterium (IBD) subjects with negative (-) and positive (+) 
correlation estimates to diseases respectively, in relation to control cases in the study. Faecalibacterium (CD) 
value highlighted with * (p= 0.05 – 0.1) showed some positive (+) correlation estimates to disease in relation to 
control but not significant. 
Components p-values 
(Estimates Direction,+/-) 
IBD CD UC 
AV_COMP1 (Faecalibacterium) 0.036** 
(+) 
0.096* 
(+) 
0.129 
(+) 
AV_COMP3 (Dialister) 0.324 
(-) 
0.595 
(-) 
0.102 
(-) 
AV_COMP4 (Haemophilus) 0.747 
(+) 
0.443 
(-) 
0.165 
(+) 
AV_COMP5 (Enterobacteraceae) 0.626 
(+) 
0.485 
(+) 
0.049** 
(-) 
AV_COMP6 (Bacteroides) 0.254 
(-) 
0.113 
(-) 
0.201 
(-) 
 
 
Figure 3.5.1: Binary Logistic Regression analysis on MCR data. ROC curve characterisation of the IBD data in 
the model is specific but lowest in sensitivity. Area under ROC curve is acceptable (≥ 0.5). 
In the MCR data, Faecalibacterium (Comp1, p=0.036) and Enterobacteroceae (Comp5, 
p=0.49) were statistically significant (Table 4.5.1), regression estimates correlating 
positively and negatively respectively as potential candidates in IBD and UC diagnotics in 
the samples under studied versus control samples. Although there was a positive correlation 
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for Faecalibacterium in CD subjects but not statistically significant (Comp1, p=0.096). 
Figure 4.5.1 gives an overview of the fit of the statistical model used, which was acceptable 
for each diagnosis (ROC curve > 0.5). 
b.) Probe Screening data 
Similar analysis as in MCR data, performed on probe peak height (PH) values, normalised 
with universal probes, significantly implicated Haemophilus (Probe_13, p=0.028) and 
Dialister (Probe_6, p= 0.058) with negative and positive correlations estimates respectively 
in the labelled samples in CD and UC (Table 3.5.2). The constant regression estimates (p= 
0.031) as shown, was significant and negatively correlating to UC, is suggestive of an 
unexplained factor in the model. As in the MCR data, the fit of the model was deemed 
satisfactory (ROC curve > 0.5).   
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Table 3.5.2: Binary Logistics Regression analysis of Probe Data. Positive (+) estimated correlation for both 
diseases CD (Haemophilus) and UC (Dialister) in relation to control data. Probe significant (p<0.05) for each 
disease is highlighted** (marginally significant* for Haemphilus [IBD]). 
Probes p-values 
(Estimates Direction, +/-) 
IBD CD UC 
NP_3H (E. coli) 0.4 
(+) 
0.761 
(+) 
0.437 
(+) 
NP_6H (Dialister) 0.405 
(+) 
0.993 
(+) 
0.058* 
(+) 
NP_8H (Faecalibacterium) 0.398 
(-) 
0.919 
(+) 
0.212 
(-) 
NP_13H (Haemophilus) 0.078* 
(-) 
0.028** 
(-) 
0.227 
(+) 
NP_16H (Enterococcus) 0.471 
(+) 
0.194 
(+) 
0.514 
(+) 
NP_18H (Lactobacillus) 0.189 
(+) 
0.174 
(+) 
0.1 
(+) 
Constant 0.837 
(-) 
0.458 
(-) 
0.031** 
(-) 
 
 
Figure 3.5.2: Binary Logistics Regression analysis of Probe Data. ROC curve expresses the quality of data 
analysed in terms of specificity and sensitivity  (ROC curve > 0.5) in the model used 
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4. Discussion 
4.1 DNA purity 
The purity of DNA preparation is essential for sensitive and useful biological analysis. The 
evaluation of quality in the extracted bacterial DNA from the children samples, showed 
some inconsistences in concentration within reference ranges of pure DNA (≥ ~1.8 or ≤ 
~2.0) and can be otherwise expected from the complex human faecal matter. (Li et al., 2003) 
Degraded products visualised at the bottom of the gel column may have affected this 
measurement. It may as be speculated that the repeated thawing and freezing of this sample 
over time can be responsible for any effect of DNA quality. (Li, et al., 2003) However, these 
degraded products could be RNA or sheared DNA but treatment with RNAse may have 
excluded RNA. Similary, despite using the highly comparable commercial kits, QIAamp® 
DNA Stool Mini Kit (Li, et al., 2003; McOrist, et al., 2002), for the extraction and DNA 
purification method, results obtained from the extraction and purification of the human 
faecal bacterial DNA in the samples under study here, may have reflected individual 
differences in extraction efficacy as there was no trend of uniform effect of the degraded 
products on concentration. (McOrist, et al., 2002) 
The microbiota profiling analysis utilised the PCR amplified 16S rRNA gene as the 
established genetic marker for microbial community profiling, compared to previously 
reported studies by Li M et al (2003) as appropriately effective in the profiling of the gut 
microbiota. Therefore, the extraction method produced DNA eluates devoid of PCR 
inhibitors (McOrist, et al., 2002). In other words, the degraded products are no impediment 
to such analysis utilising the 16S gene as has been demonstrated in results presented in this 
study. 
4.2 MCR prediction of abundant bacterial sequences (species) in cohort 
The rigors of finding structure in an environment of mixed population was initially possible 
with the proven multivariate technique which is applicable to gut bacterial community (K. 
Rudi, et al., 2007; Trosvik, et al., 2007)  as in the diverse bacterial sequences generated in 
mixed DNA pool in the cohort. By doing this, were able to explore selected DNA samples 
further, and the study on bacterial diversity and richness can thus be enhanced on other 
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samples in the study. As demonstrated by Trosvik P, et al (2007), their method that applys 
MCR showed that determing species of high-richness among community members may be a 
potential disadvantage of MCR application to prediction of total abundance in a data set but 
nonetheless can expose subgroups within a complex data set. Hence, to truly achieve the aim 
of mining the gut microbiota and establish biodiversity for diagnostic potential, the 
understanding of the relevant and representative microbial species is essential in the large 
data sets that are analysed in microbial studies. (K. Rudi, et al., 2007) 
Generally, a consensus on the dynamics of intestinal microbiota imbalances has been 
difficult owing to differences in approach, specimens used and conflicting findings in 
literature. However, from microbial 16S sequence resolution, a prediction of most bacterial 
representation in the cohort sequence data was reported. Enterobacteriaeceae representation 
in most of the mixed samples sequence in this cohort study mirror that found in faecal 
analysis with increased concentration of enterobacteria in CD, which have implication in 
intestinal virulence (Sokol, Lay, et al., 2008) and in some other cases represented as 
Enterobacter cowanii, a relative within the family (Mondot, et al., 2011). Hence, it is not a 
coincidence predicting the increased abundance expressed in our samples. Similarly, an 
increased abundance of Faecalibacterium and Bacteroides was also observed in overall 
sequences-MCR components comparism matrix as well. However, contrary to this MCR 
prediction, this groups are thought to be deplected in published works from CD studies in 
relation to control subjects. (Joossens et al., 2011; Sokol, Lay, et al., 2008; Sokol, Pigneur, et 
al., 2008) The least representation of Dialister and Haempohilus components in these 
sequences is noted with the former decreased in CD patients (Joossens, et al., 2011; Sokol, 
Pigneur, et al., 2008) while the later exposed a previously uncharacterised gut phylotype in 
literature.  
Importantly, these suggestions from MCR prediction are based on structure within the mixed 
sequences. In this view, further work such as the probe assay results can establish its use in 
IBD diagnostic. 
4.3 Clone library evaluation of MCR prediction 
There are basically three groups of highly abundant bacterial phyla represented in the 
selected children faecal DNA sequenced from cloning with frequently reported dysbiosis 
suggesting implication in the pathogenesis of IBD. Submissions here in relation clone library 
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results is deemed a representation of a subset of the cohort data based on MCR selected 
samples for cloning and the pure sequences determined. As a matter of fact, they showed 
biodiversity as achieved by previous study establish microbiota species by comparison to 
healthy controls from the cloning of bacterial 16S genes from six faecal samples but 
however, a larger library (25 000 clones) was generated for both sets. (Manichanh et al., 
2006) 
 Within the clone library, retrieved sequences as matched included an array of commensal 
bacteria subgroups, Dialister, E. coli, Faecalibacterium and Subdoligranulum, which have 
otherwise been previously reported in literature to be implicated in gut bacteria dysbiosis 
between IBD and healthy subjects. (Joossens, et al., 2011; Mondot, et al., 2011; Sokol, 
Pigneur, et al., 2008) Interestingly, Haemophilus which has not been implicated previously 
was not infered from control cases in the children studied but represented in the diseased 
subjects. As such may have to be explored further for potential in diagnostic development. A 
small fraction of the library also harbour some “unclassified” bacterial group of the phylum 
Firmicutes. The biodiversity and reduced abundance of subgroups within the Firmicutes 
phylum have been interpreted in many studies but in some inclined to dorminance in CD 
subjects and this cohort clone library reflects Firmicutes richness in IBD cases. (Sokol, 
Pigneur, et al., 2008) Although biodiversity within Bacteroidetes phylum seem conserved 
(Sokol, Lay, et al., 2008), and the library in these study showed that there is an increase in 
the Bacteroidetes species abundance versus the control especially in CD (Manichanh, et al., 
2006).   
In the view that the clone library is to reflect the cloning sample selected due to its high 
MCR scores in the predict components. The identification of most of these components from 
the clone library very much justifies its selection criteria in such a way as to establish 
Enterococcus as the dorminant group of the Enterobacteriaceae family identified in the 
mixed sequence resolution. This should be somewhat increased in IBD cases especially CD 
although some reports has stipulated a decrease (Frank et al., 2007; Mondot, et al., 2011; 
Sokol, Lay, et al., 2008), and this happened to be significantly correlating to UC instead by 
our binary logistic model in relation to control. Similary, Faecalibacterium predicted in the 
MCR analysis was equally significant  by the same model in IBD cases and only marginally 
correlating to CD, which is also antagonistic to previous reports by Sokol et al (2008).   
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It would also be worthy to note that the unculturable TM7 phylotypes which are usually 
found in natural environmental habitats and now associated with higher diversity in CD than 
in controls and UC, only recorded one representation in CD clones matched. However, 
would have expected much in this cohort given that the samples collected were from early 
and untreated cases of IBD where TM7 phylotypes are suggested to be community 
modulator or trigger of inflammation in the early stages of IBD. (Kuehbacher, et al., 2008) 
It will also be interesting to point out that certain bacteria species which has been previously 
reported in faecal populations were missing in the clone library matches, such as 
Bifidobacteria which is demonstrated to be found in 80% of cultivable feacal bacteria with 
probitic potential (Picard et al., 2005) and an also equally gut beneficial Lactobacillus was 
predominant in UC and absent or almost absent in controls and CD. (Sokol, Lay, et al., 
2008) Control samples may be non-IBD diagnosed but could as include IBS (Inflammatory 
Bowel Syndrome) cases, with similarities in symptoms to IBD. Similarly, this subjects may 
as been IBD without full manifestation in diagnosis. Essentially, in most reported studies 
where clone libraries have been generated from samples, they generally involved subjects 
undergoing or have undergone treatment which is different in this cohort of untreated and 
early diagnosed patients. (Sokol, Lay, et al., 2008)   
4.4 Correlation in the MCR data and Probe screening  
With respect to the MCR prediction, analysis implied significance in two bacteria groups, 
Faecalibacterium (IBD) and Enterobacteriaceae (UC). However, the probe data analysed, 
rather exposed two different bacterial species significantly correlating to CD (Haemophilus) 
and UC (Dialister) but within the five resolved species predicted by MCR. In order words 
the probe data regression showed the specificity of the target probes in IBD disease 
screening and its relevance to diagnostics. It is evident that this deduction from the probe 
analysis of this two species, reflects the abundance profile as compared to the controls, from 
the clone library of the representative samples. This would not be suprising and validates the 
probes that were designed with the sequences in the clone library as templates. 
As time could permit, few probes were evaluated and even fewer screened, it may be said 
that the narrow results maybe impacting on confirmating the actual biodiversity in this 
cohort. Even though, a probe targeting the E. coli species group was screen, its worthy of 
note that this highly report bacteria group (Manichanh, et al., 2006; Mondot, et al., 2011; 
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Sokol, Lay, et al., 2008) had no significance in this reported data and not predicted by MCR.  
Conversely, within the probe data statistics model, there remains a significant constant of 
unexplained factor in UC which may be driving the results output. It would thus enhance 
confirmation and conclusion to explore effects such as age within the data set. Although, this 
was evaluated with potential but not as yet reported as results were inconclusive. 
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4.5 Further work 
In order to further investigate the biodiversity of the gut microbiota and implication to IBD 
against control subjects it would be a suggestion to recruit even more samples with equal 
number of diagnosed subjects, that is for example; 100 controls, 100 UC and 100 CD 
patients in the cohort. Conversely, a randomly selected control group, instead of non-IBD 
controls with IBD symptoms reported in this cohort. In this way, any diagnostic potential 
could be validated and probably inconsistency better understood if not completely avoided. 
The clone library can as well be linked more to the MCR components by generating a Local 
Blast database library and search for component frequency in each of the cloned sequences. 
As there were more probes designed than could be evaluated or screened and potential more 
windows to consider in the probe design to generate even more probes. An assay of a greater 
number of more 16S probes will enhance the realisation of an extensive enteric gut 
biomarker for IBD. Similary, with larger probe set, a microarray platform could be 
construsted and simulateneously screened for any correlations to the disease. In addition, the 
Luminex techonology as has been used in microbial community detection and biomarkers 
screening, is an ideal platform for clinical validation for the development of companion 
diagnostics. 
Given that the samples analysed were patients recruited with early IBD symptoms and it 
would also be interesting to analyse the gut microbial diversity of same individuals post 
treatment. This should be particularly of interest to the management of the disease as is the 
confirmation of the early diagnostic potential of IBD from the aim of this study. 
In another hand, other statistical approach and model could be used, such as analysis of 
variance  (ANOVA) to establish disease correlation against the control group. 
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5. Conclusion 
The evaluation of the children faecal samples highlighted the biodiversity of the gut 
microbiota. Similarly MCR predicted bacterial species and probes specific to bacterial 
species that could be targeted for potential addition to the already novel GA screening tools 
aimed at establishing the IBD diagnostic platform. The selective targets are Dialister and 
Haemophilus, as implicated in UC and CD respectively. This may have wider implication 
for early IBD diagnostic if followed up with extensive validation.   
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Appendix 
Table 2.1.1A: Samples and Diagnosis. 
Sample 
ID Diagnosis 
Sample 
ID Diagnosis 
Sample 
ID Diagnosis 
7 CD 180 CD 6006 CONTROL 
20 CONTROL 181 CD 6007 UC 
28 CD 187 CONTROL 6008 CONTROL 
32 CONTROL 188 CD 6009 CONTROL 
35 CONTROL 191 CONTROL 6010 CD 
50 CONTROL 192 UC 6011 UC 
54 CONTROL 195 CONTROL 6013 CD 
58 CONTROL 196 CONTROL 6014 IBDU 
71 CD 198 UC 6015 CONTROL 
72 CONTROL 201 CONTROL 6016 CONTROL 
77 CONTROL 202 CD 6017 UC 
79 UC 205 CONTROL 6018 CD 
86 UC 207 CONTROL 6019 CD 
87 CONTROL 1005 CD 6021 CONTROL 
88 CONTROL 1006 CONTROL 6022 CD 
99 CONTROL 1013 UC 6023 UC 
111 CD 1028 CD 6026 UC 
119 UC 1030 CD 6028 CD 
126 UC 2024 CD 6030 CD 
130 CONTROL 2025 IBDU 6032 CD 
131 CD 5009 CONTROL 6033 UC 
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136 CONTROL 6001 UC 6034 CD 
158 CONTROL 6003 CD 6035 CD 
163 CD 6004 CONTROL 6036 CD 
172 CD 6005 UC 6038 UC 
 
Table 2.1.2A: Diagnosis and classification criteria for IBD as either CD, UC or IBDU. 
Classification  Diagnosis features  
CD •  Clinical features including abdominal pain, diarrhoea 
and weight loss 
•  Macroscopic appearance at operation or endoscopy: 
segmental, discontinuous, and/or patchy lesions with or 
without rectal involvement, discrete or apthous 
ulcerations, fissuring or penetrating lesions, 
cobblestone or strictures 
•  Radiological evidence of stenosis in the small bowel, 
segmental colitis or findings of fistulae 
•  Histologic evidence of transmural inflammation or 
epithelial granulomas with giant cells.  
UC •  A history of diarrhoea and or blood/pus in stool 
•  Macroscopic appearance at endoscopy, with 
continuous mucosal inflammation affecting the rectum 
in continuity with some or the entire colon 
•  Microscopic features on biopsy compatible with UC 
•  No suspicion of CD on small bowel ileocolonoscopy 
or biopsy.  
  Patients with inconclusive or divergent endoscopy and histopathology 
according to CD or UC criteria were classified as IBDU.  
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Chimeric sequence removal  with chimera slayer 
algorithm in mothur : 
1. Sequences in fasta format  
2. Mothur (program) 
3. >summary.seqs (fasta=….) 
4. May do: Filtrate sequences (n, homopolymers, primers, seq that 
don`t have the expected length) 
5. >align.seqs(candidate=….., template=……, ksize=8)  
 template file: rRNA16S.gold.NAST_ALIGNED.fasta 
6. >filter.seqs(fasta=…..align-template.fasta, vertical=T) 
7. >chimera.slayer(fasta=…filter.fasta, template=aligned.filter.fasta, 
minbs=95) chimera removal base don the chimara slayer 
algorithm 
8. >remove.seqs(accnos=…accnos, fasta=…unique.fasta, 
names=….names) 
9. >summary.seqs(fasta=unique.pick.fasta) 
10. create names file: >unique.seqs(fasta=…..fasta) identify the 
unique sequences in a collection and generate a names file  
Figure 2.8.1A: Mothur commands (Chimeric Slayer). 
Multivariate Curve Resolution steps for bacterial mixed sequences: Commands used. 
The large set of mixed sequences -> aligned all of them -> took the aligned spectra and pre-
processed/normalized them (aligned once again, but taking only small portions (individual peaks) 
at a time to ensure that there were no small peak shifts due to differences in the retention time) 
->decided how much information that could be got out of the dataset (perform PCA and/or EFA 
[Evolving Factor Analysis] to decide. Result - number of 'significant' components which explain 
the most of variation) -> took these number of components, perform MCR (just upload the file 
with aligned spectra to the program, set the number of components to pre-determined value, 
click 'run') -> get two outputs. One contained the information on the relative amount of each of 
the components in every sample/individual of the dataset. The other had the spectral 
information on what each of the components are -> plotted the spectral information and 
basecalled -> BLASTed the sequence to identify what each of the components were. 
Figure 2.9.1A: Commands operations used for MCR of mixed bacterial sequences. 
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Table 3.2.1A: Quality of Sequences, Illustration of the Sequence quality based on the sequencer capillary 
signal. Saturated ≥8000; Good ≥2000; Moderate ≥1000 or <2000; Poor ≤1000 
Sample  
Number 
Sequence 
Quality 
Sample 
Number 
Sequence 
Quality 
Sample 
Number 
Sequence 
Quality 
7 Good 180 Good 6007 Moderate 
20 Good 181 Good 6008 Moderate 
28 Good 187 Good 6009 Poor 
32 Good 188 Moderate 6010 Good 
35 Good 191 Good 6011 Moderate 
50 Good 192 Poor 6013 Moderate 
54 Poor 195 Poor 6014 Good 
58 Good 196 Moderate 6015 Good 
71 Good 198 Good 6016 Moderate 
72 Noise 201 Good 6017 Good 
77 Saturated 202 Noise 6018 Good 
79 Good 205 Moderate 6019 Good 
86 Good 207 Poor 6021 Good 
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87 Good 1005 Moderate 6022 Good 
88 Good 1006 Good 6023 Good 
99 Good 1013 Good 6026 Good 
111 Moderate 1028 Good 6028 Good 
119 Good 1030 Moderate 6030 Good 
126 Good 2025 Moderate 6032 Moderate 
130 Good 5009 Poor 6033 Good 
131 Moderate 6001 Moderate 6034 Good 
136 Good 6003 Good 6035 Good 
158 Poor 6004 Moderate 6036 Good 
163 Good 6005 Moderate 6038 Good 
172 Moderate 6006 Moderate 6039 Noise 
 
Table 3.1.1A: DNA quality measure by Nanodrop spectrophotometry. For pure DNA, A260/280 is ~1.8 and for 
pure RNA A260/280 is ~2. DNA gel band strength and degradation are graded: Strong (+++), Good (++) and Weak 
(+). No trend was observed for the varying DNA band signals. 
Sample 
# 
Gel band 
Evaluation 
OD 
Evaluation 
Sample 
# 
Gel band 
Evaluation 
OD 
Evaluation 
Sample 
# 
Gel band 
Evaluation 
OD 
Evaluation 
Strength degradation 260/280 quality Strength degradation 260/280 quality Strength degradation 260/280 quality 
7 + + 2.15 84.01 180 + + 1.76 23.65 6007 + + 2.62 16.11 
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20 + + 1.95 43.84 181 ++ + 1.32 3.74 6008 ++ + 1.83 45.47 
28 + 0 1.79 9.5 187 + 0 6.30 2.44 6009 + +++ 2.26 98.6 
32 + 0 2.19 3.86 188   1.98 10.0 6010 +++ 0 2.26 25.73 
35 + 0 1.65 5.7 191 ++ +++ 2.20 118.41 6011 +++ 0 2.47 10.84 
50 ++ +++ 2.03 41.42 192 +++ 0 2.22 49.58 6013 + + 1.19 38.95 
54 ++ + 1.97 42.74 195 +++ 0 2.64 10.24 6014 + ++ 2.17 98.99 
58 ++ +++ 2.13 149.05 196 ++ +++ 2.23 111.11 6015 ++ +++ 2.17 46.87 
71 + + 1.97 20.6 198 + 0 2.65 4.39 6016 +++ + 1.71 15.11 
72 + 0 1.99 26.92 201 +++ 0 2.77 7.66 6017 + 0 2.17 60.8 
77 ++ + 1.88 9.45 202 +++ + 2.17 33.71 6018 + ++ 1.92 20.86 
79 +++ +++ 1.86 47.32 205   1.99 10.0 6019 + 0 1.79 8.31 
86 +++ ++ 1.59 11.62 207 + +++ 2.23 89.56 6021 + 0 2.24 5.6 
87 +++ 0 1.84 26.96 1005 ++ ++ 2.21 58.11 6022 + 0 2.21 23.43 
88    10.0 1006 +++ + 2.25 39.45 6023 +++ 0 2.02 117.56 
99 ++ + 1.85 65.32 1013 ++ + 2.31 35.13 6026 +++ +++ 2.10 6.34 
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111 ++ +++ 1.96 88.05 1028 ++  2.35 10.0 6028 + 0 2.09 6.45 
119 ++ 0 2.00 17.96 1030   2.51 6.0 6030 + 0 2.10 79.47 
126 + + 2.00 35.3 2025 +  2.17 10.0 6032 ++ +++ 2.20 118.81 
130 + + 1.97 35.19 5009 + + 2.07 31.35 6033 + +++ 2.15 33.88 
131 + + 2.11 29.94 6001 ++ + 2.34 18.08 6034 + + 2.15 43.29 
136 + + 2.08 41.09 6003 + + 2.43 15.59 6035 + + 2.04 123.71 
158 + 0 0.71 1.35 6004 + + 2.36 32.11 6036 ++ ++ 1.83 12.77 
163   2.11 10.0 6005 + +++ 2.32 66.59 6038 + 0 2.17 106.68 
172   1.87 10.0 6006 + 0 2.71 16.7 6039 +++ +++ 2.45 6.87 
 
Table 3.3.2A: Clone library. Sequences match by Ribosomal Database Project. 
Diseas
e 
Clone ID Domain Phylum Class Order Family Genus 
CD 111.2 Bacteria Verrucomicrobia Verrucomicrobiae Verrucomicrobiales Verrucomicrobiaceae Akkermansia   
CD 111.16 Bacteria Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae Alistipes 
CD 172.18 Bacteria Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae Alistipes 
CON 5009.25 Bacteria Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae Alistipes 
CON 5009.5 Bacteria Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae Alistipes 
CD 111.23 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
CD 111.9 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
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CD 172.12 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
CD 172.31 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
CD 6034.21 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
CD 6034.28 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
CD 6036.35 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
CD 6036.4 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
CON 32.5 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
CON 5009.17 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 198.1 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 198.26 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 198.28 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 198.36 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 198.37 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 198.39 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 6005.28 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 6005.8 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 86.1 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 86.12 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 86.17 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 86.2 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 86.2 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 86.26 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 86.3 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 86.32 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 86.9 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 87.1 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 87.25 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
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UC 87.28 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
UC 87.9 Bacteria Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
CD 6032.39 Bacteria Firmicutes Clostridia Clostridiales Incertae Sedis XIV Blautia 
CD 111.37 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Butyricicoccus 
CD 6036.21 Bacteria Firmicutes Clostridia Clostridiales Clostridiaceae (Subfamily: 
Clostridiaceae 1) 
Clostridium 
CD 6034.7 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
CON 5009.11 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
CON 5009.12 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
CON 5009.27 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
CON 5009.32 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
CON 5009.9 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.11 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.12 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.14 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.15 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.16 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.19 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.2 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.2 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.21 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.23 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.32 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.34 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.36 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.38 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
UC 6005.4 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
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CD 172.1 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.21 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.23 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.25 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.26 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.27 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.29 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.3 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.33 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.34 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.35 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.38 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.39 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 172.6 Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 
CD 1030.13 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.16 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.17 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.18 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.2 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.21 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.23 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.3 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.31 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
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CD 1030.33 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.34 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.37 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.7 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 1030.8 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 172.13 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 172.24 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 6034.1 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 6034.13 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 6034.31 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.11 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.12 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.15 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.16 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.19 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.2 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.21 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.22 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
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CON 32.23 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.24 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.25 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.28 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.3 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.3 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.35 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.36 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.37 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.4 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.6 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CON 32.8 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.1 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.11 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.12 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.16 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.17 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.2 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
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UC 119.21 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.22 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.23 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.24 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.25 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.26 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.29 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.3 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.31 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.33 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.35 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.36 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.39 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.4 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.5 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
UC 119.8 Bacteria Proteobacteria Gammaproteobac
teria 
Enterobacteriales Enterobacteriaceae Escherichia/Shigella 
CD 6032.21 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
CON 6009.19 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
CON 6009.23 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
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CON 6009.9 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
UC 86.14 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
UC 86.19 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
UC 86.21 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
UC 86.25 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
UC 86.29 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
UC 86.3 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
UC 86.38 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
UC 86.5 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 
CD 6036.3 Bacteria Firmicutes Bacilli Lactobacillales Carnobacteriaceae Granulicatella 
CD 6036.5 Bacteria Firmicutes Bacilli Lactobacillales Carnobacteriaceae Granulicatella 
CD 6034.14 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6034.19 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6034.2 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6034.22 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6034.25 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6036.1 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6036.19 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6036.2 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6036.2 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6036.23 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6036.27 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
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CD 6036.29 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6036.3 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6036.32 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6036.33 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6036.37 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.1 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.14 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.16 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.17 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.2 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.21 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.22 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.23 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.24 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.27 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.32 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.34 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.35 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
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UC 198.38 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.4 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.7 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
UC 198.8 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae Haemophilus 
CD 6032.31 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.12 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.15 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.16 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.2 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.22 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.24 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.3 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.3 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.31 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.33 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.37 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.38 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.39 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.4 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.5 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.6 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.7 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 
UC 6001.11 Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus  
CD 6032.25 Bacteria Firmicutes Bacilli Lactobacillales Streptococcaceae Lactococcus 
CD 6032.6 Bacteria Firmicutes Bacilli Lactobacillales Streptococcaceae Lactococcus 
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CON 5009.34 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Lactonifactor 
CON 32.33 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Megamonas 
UC 198.6 Bacteria Proteobacteria Betaproteobacteri
a 
Neisseriales Neisseriaceae Neisseria 
UC 6005.24 Bacteria Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Odoribacter 
CD 172.2 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillibacter 
CON 5009.29 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillibacter 
CON 5009.33 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillibacter 
CD 111.3 Bacteria Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides 
CD 111.32 Bacteria Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides 
CON 6009.6 Bacteria Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides 
CON 32.26 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae Phascolarctobacteriu
m 
UC 6005.37 Bacteria Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 
UC 6005.7 Bacteria Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 
CON 6009.2 Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae Roseburia 
CON 6009.4 Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae Roseburia 
CON 6009.5 Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae Roseburia 
CD 6032.19 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcus 
CD 6032.26 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcus 
CD 6032.28 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcus 
CD 6032.4 Bacteria Firmicutes Bacilli Lactobacillales Streptococcaceae Streptococcus 
CD 6036.24 Bacteria Firmicutes Bacilli Lactobacillales Streptococcaceae Streptococcus 
CD 6036.31 Bacteria Firmicutes Bacilli Lactobacillales Streptococcaceae Streptococcus 
CD 6036.6 Bacteria Firmicutes Bacilli Lactobacillales Streptococcaceae Streptococcus 
CD 6032.11 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.12 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.14 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
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CD 6032.17 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.18 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.22 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.23 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.27 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.29 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.3 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.32 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.35 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.37 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.7 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.9 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6032.15 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 6034.26 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CON 6009.1 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CON 6009.7 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
UC 6005.17 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
UC 6005.29 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
UC 6005.35 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 
CD 172.19 Bacteria Proteobacteria Betaproteobacteri
a 
Burkholderiales Alcaligenaceae Sutterella 
CD 6036.1 Bacteria Firmicutes Clostridia Clostridiales Peptostreptococcaceae unclassified_"Peptost
reptococcaceae 
CD 6032.13 Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified_Lachnos
piraceae 
CD 6034.24 Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified_Lachnos
piraceae 
CON 5009.14 Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified_Lachnos
piraceae 
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CON 5009.2 Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified_Lachnos
piraceae 
CD 6034.3 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae unclassified_Pasteure
llaceae 
CD 6034.6 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae unclassified_Pasteure
llaceae 
CD 6036.13 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae unclassified_Pasteure
llaceae 
UC 198.11 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae unclassified_Pasteure
llaceae 
UC 198.12 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae unclassified_Pasteure
llaceae 
UC 198.15 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae unclassified_Pasteure
llaceae 
UC 198.3 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae unclassified_Pasteure
llaceae 
UC 198.31 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae unclassified_Pasteure
llaceae 
UC 198.33 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae unclassified_Pasteure
llaceae 
UC 198.9 Bacteria Proteobacteria Gammaproteobac
teria 
Pasteurellales Pasteurellaceae unclassified_Pasteure
llaceae 
CON 6009.28 Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae unclassified_Ruminoc
occaceae 
UC 86.36 Bacteria Firmicutes Clostridia Clostridiales Veillonellaceae unclassified_Veillonell
aceae 
CD 111.4 Bacteria Firmicutes unclassified_"Firm
icutes 
      
CD 6032.15 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
CD 6032.33 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
CD 6032.34 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
CD 6034.32 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
CD               
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CD 6036.28 Bacteria Firmicutes unclassified_Firmi
cutes 
      
CD 6036.7 Bacteria TM7 TM7_genera_ince
rtae_sedis 
      
CON 32.1 Bacteria Bacteroidetes Bacteroidia Bacteroidales unclassified_Bacteroidale
s 
  
CON 5009.2 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
CON 6009.22 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
UC 6005.25 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
UC 6005.3 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
UC 86.24 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
UC 86.28 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
UC 86.39 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
UC 86.4 Bacteria Firmicutes Clostridia Clostridiales unclassified_Clostridiales   
 
Table 3.3.3A: MCR data showing average component frequency for each sample. Control=1,CD=2, UC=3 and 
IBDU=4 
Sample ID Disease Diagnostic av comp1 av comp3 av comp4 av comp5 av comp6 
1005 2 0.09662275 0.10094035 0.1778055 1.15541 0.266845 
1006 1 0.025005 0.01839855 0.0144962 1.73841 0.03794785 
1013 3 0.8957145 0.00305693 0.0493003 0.11463055 0.592095 
1028 2 0.0168919 0.0345116 0.02519813 1.71786 0.01891755 
1030 2 0.00740699 0.02378553 0.01942797 1.76478 0.0091893 
111 2 0.51816133 0.0831854 0.08442183 0.0861447 0.83792167 
119 3 0.0386527 0.02281594 0.03844705 1.70626 0 
126 3 0.62727533 0.30694733 0.198882 0.17261667 0.302465 
130 1 0.304723 0.0714056 0.104621 0.345518 0.867447 
131 2 0.292211 0.217679 0.593322 0.234191 0.359489 
136 1 0.27838 0.17847967 0.643364 0 0.49705033 
158 1 0.2777785 0.00615805 0.162374 0 1.15297 
163 2 0.40003633 0.10785117 0.07688933 0.786704 0.306434 
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172 2 0.2502545 0.43028 0.03650655 0.455322 0.583656 
180 2 0.3135775 0.0676525 0 1.10081 0.29715 
181 2 0.4978575 0.02679835 0.0911631 0.67396425 0.434388 
187 1 0.182942 0 0.124803 1.12592 0.355492 
188 2 0.5983775 0.05192515 0.07374915 0.649892 0.2713805 
191 1 0.02105155 0.01310901 0.00775747 1.699615 0.08128055 
192 3 0.657207 0.0881509 0.140398 0.047746 0.635054 
195 1 0.5114955 0.00440618 0.08664225 0.0509506 0.921095 
196 1 0.46484233 0.159627 0.0843206 0.737546 0.231428 
198 3 0 0 1.295265 0.485519 0.03824685 
20 1 0.43667967 0.0170419 0.0975704 1.062747 0.13136883 
201 1 0.13187697 0 0.12564367 1.11919667 0.36285867 
202 2 0.127601 0.130105 0.134221 1.33994 0 
2025 4 0.93864133 0.10505987 0.0945611 0.0721556 0.347344 
205 1 0.5822895 0.04801625 0.10945465 0.41525055 0.4709825 
207 1 0.311019 0.20256 0.546623 0.374602 0.20931 
28 2 0.6704415 0.160596 0.0613596 0.370275 0.37944 
32 1 0.04704057 0.03782793 0.03812417 1.67478 0.01684512 
35 1 0.17998733 0.0084628 0.0369488 1.36074 0.20583367 
50 1 0.79215667 0.419869 0.24483633 0 0.08123027 
5009 1 0.14277633 1.39399667 0.03259643 0.02722243 0 
54 1 0.81685967 0.10989567 0.11237667 0.191019 0.350344 
58 1 0.4348495 0.02663475 0.1381545 0.00723789 1.0045865 
6001 3 0 0.5696545 0 0.2945825 0.911681 
6003 2 0.672149 0.5088505 0.2700145 0 0.06372525 
6004 1 0.413348 0.1166487 0.15985207 0.43103033 0.50239167 
6005 3 0.06622063 1.39467667 0.00116812 0.10678643 0.04393467 
6006 1 0 0.543341 0 0.4984615 0.722222 
6007 3 0.030076 0.0586965 0.0003734 0 0 
6008 1 0.372814 0.26736 0.301091 0.6086495 0.0352994 
6009 1 1.30767333 0 0 0.17087133 0.154097 
6010 2 0.48467133 0.0250996 0 0.921392 0.27751867 
6011 3 0.51100233 0.220211 0.22335467 0.13185913 0.50389333 
6013 2 0.231449 0.12324673 0.65559333 0.67316167 0.010138 
6014 4 0.155117 0.0368242 0.02107873 1.510605 0.09391367 
6015 1 0.609845 0.052221 0.00850015 0.7537705 0.2387575 
6016 1 0.6064225 0.0866431 0.2063235 0.294706 0.444143 
6017 3 1.197365 0 0 0.3812485 0.10411235 
6018 2 0.810702 0.04685035 0.1048536 0.08954665 0.5524885 
6019 2 0.682762 0.0533344 0.00886335 0.2555735 0.644604 
6021 1 1.184275 0.0662752 0.0050822 0.145912 0.20236 
6022 2 0.07606355 0.06641105 0.09182045 1.365915 0.1597211 
6023 3 0.9823295 0.06487415 0.01284244 0.1596155 0.3957065 
6026 3 0.01129195 0.01243805 0.0118152 1.75807 0 
6028 2 0.222192 0.0965146 0.052081 1.34487 0.0712833 
 85 
6030 2 1.0196655 0.04346545 0.1774935 0.03632865 0.3212835 
6032 2 1.18717 0.07119985 0.0102897 0.241384 0.1453905 
6033 3 0.07865965 0 0.2021825 1.510615 0 
6034 2 0.3155155 0.0788566 0.7212625 0.6128485 0 
6035 2 0.7425085 0.00256881 0.1443815 0 0.693175 
6036 2 0.2415125 0.0694424 0.945125 0.3673285 0.06244665 
6038 3 0.738363 0.2405225 0.191375 0.04415315 0.40472 
7 2 0.0692445 0.02751875 0.0094975 1.672575 0.04123755 
71 2 0.172603 0.03256627 0.094674 1.50565 0.00268708 
77 1 0.05496753 0.0569889 0.0459642 1.62066333 0.0136956 
79 3 0.296495 0.141944 0.2653185 0.937086 0 
86 3 1.20533 0.0114154 0 0.238771 0.151405 
87 1 0.1975235 0 0.129847 0.0168531 1.31595 
88 1 0.610152 0.0571016 0.136338 0.0785317 0.718745 
99 1 0.773552 0.0195371 0.0882845 0.0866485 0.661091 
  
Table 3.4.1A: List of the 19 probes designed and evaluated with targets and non-targets from the clone 
library. 
Probe Number Sequence Genus (Target) 
Probe_1 CCTCCAGTTTATCACTGGC E.Coli 
Probe_2 TCAAGCTTGCCAGTATCAGATGC E.Coli 
Probe_3 GCCTCAAGGGCACAAC E.Coli 
Probe_4 CGCGGGTTCGCTTCTCTTTGTTGAC Dialister 
Probe_5 GACATTGATCGCGATCTGCAGAAATGC Dialister 
Probe_6 AAGAACTCCGCATTTCTGC Dialister 
Probe_7 ACAACGCTTGTGACCTAC Faecalibacterium 
Probe_8 CGTAGTTAGCCGTCACTTC Faecalibacterium 
Probe_9 CGGACAACGCTTGTGAC Faecalibacterium 
Probe_10 CCCAGTATGAAATGCAATTCCC Haemophilus 
Probe_11 ACCGCAACATTCTGATTTGC Haemophilus 
Probe_12 CGCTTCCCTCTGTATACGC Haemophilus 
Probe_13 TCGCTTCCCTCTGTATACG Haemophilus 
Probe_14 CGATTAACGCTCGCAC Haemophilus 
Probe_15 CCTCCAACACTTAGCACT Enterococcus 
Probe_16 CCCTCCAACACTTAGCA Enterococcus 
Probe_17 CCTGTCACTTTGCCC Enterococcus 
Probe_18 CCTGTTTGCTACCCATACTTT Lactobacillus 
Probe_19 GAGTTCCACTGTCCTCTT Lactobacillus 
Probe_20 CCATGCACCACCTGTAT Lactobacillus 
Probe_21 CTTGCTTCTCTTTGTTTAACGC Faecalibacterium 
Probe_22 GCTTCTCTTTGTTTAACGCC Faecalibacterium 
Probe_23 GGTCTTGCTTCTCTTTGTTTAAC Faecalibacterium 
Probe_U (UNI01) CGTATTACCGCGGCTGCTGGCA  Universal 
 
Table 3.4.2A: Probe Data showing normalised “peak height” (PH) 
Sample 
Number NP_3H NP_6H NP_8H NP_13H NP_16H NP_18H P_Universal 
7 0.965185 51.82609 216.7273 59.10744 143.04 3.445087 52472 
28 0.398071 35.64063 6.912121 50.68889 57.025 2.04574 18447 
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71 0.528562 0 11.44094 28.77228 0 2.310016 23602 
79 0.391951 106.7059 17.87192 0 14.11673 4.365824 26210 
86 0.096728 7.478723 1.604412 60.25714 114 1.151515 30104 
111 0.013506 29.8498 22.54328 62.41322 92.09756 3.186498 57739 
119 1.313894 135.75 67.875 0 72.9403 4.49586 32488 
126 0.108243 4.167482 11.21382 20.1716 85.225 2.751412 25054 
131 0.018779 23.02703 2.843159 4.689908 42.6 5.496774 20079 
163 0.391379 6.286022 7.066076 48.98883 153.8421 2.798022 68611 
172 0.103516 0 5.818182 0 0.70137 2.064516 3957 
180 0.683317 37.77949 0 31.89177 237.6452 3.906151 55413 
181 0.013017 10.95796 3.426291 23.61812 105.7681 2.407786 53922 
188 0.207226 0 4.079533 122.25 0 2.324144 54459 
192 0.016413 0 9.102508 25.76235 0 2.57544 63641 
198 0.005523 0 115.7705 2.337637 108.6462 11.80936 49993 
202 0.839827 0 3.652611 0 0 3.951788 56663 
1005 0.446633 54.9881 14.52516 50.75824 124.8378 7.711185 30982 
1013 0.005176 143.9412 8.220605 92.92405 103.3944 2.150894 54072 
1028 1.020326 171.5641 32.79902 0 89.21333 6.144169 44117 
1030 1.164364 136.6889 72.36471 46.24812 74.10843 5.42895 39406 
2025 0.005126 12.6826 4.307143 90.86301 157.9286 1.594855 43103 
6001 0.010704 141.3333 16.16422 78.74286 2.199521 0.656112 35776 
6003 0.04615 3.104255 14.11935 59.14865 61.64789 3.276198 29416 
6005 0.01027 64.91111 2.507296 36.06173 78.94595 1.947333 21571 
6007 1.42129 110.85 33.84733 134.3636 94.34043 3.359091 29601 
6010 0.524477 96.52941 19.61355 54.0989 87.91071 2.283395 33060 
6011 0.117002 5.372159 10.6087 88.98824 0 4.339644 56321 
6013 0.435301 0 40.43452 2.975471 52.65891 6.11982 45041 
6014 0.902774 13.20513 11.28326 200.2778 0 3.221626 50639 
6017 0.168671 35.77907 4.478894 45.92537 96.15625 0.724682 22810 
6018 0.046493 49.9 8.754386 69.30556 97.84314 3.015106 32726 
6019 0.076756 75.56364 24.7381 30.11594 62.02985 2.581366 27769 
6022 0.71022 15.03546 76.62651 27.06383 94.92537 4.937888 41219 
6023 0.006026 20.15835 5.554692 61.95333 127.3014 1.278619 70161 
6026 1.174614 122.0492 91.91358 0 225.6061 6.209341 53762 
6028 0.685225 85.14815 42.57407 35.55155 54.7381 6.315934 45776 
6030 0.029923 39.84615 5.853107 24.37647 45.04348 1.248193 15402 
6032 0.096943 18.46774 8.178571 14.87013 9.956522 0.555556 8583 
6033 2.263868 39.23529 46.80702 7.847059 47.64286 6.262911 20664 
6034 0.353659 0 18.65868 2.670094 89.02857 1.859189 23377 
6035 0.004894 18.43609 7.710692 67.48624 156.5106 2.244051 53849 
6036 0.227696 8.344444 3.413636 0.97406 8.075269 1.203526 5694 
6038 0.017297 3.567985 4.257768 46.83544 63.7931 2.306733 24914 
6039 0 0 1.882353 0 0 1.103448 541 
20 0.29715 0 51.57576 130.9231 0 1.295775 48858 
32 1.001237 0 45.75472 0 0 3.479197 19583 
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35 0.602475 35.21795 6.782716 67 76.30556 2.051531 21773 
50 0 0.270887 2.222615 4.278912 0 0.161158 6329 
54 0.081458 0 5.463547 57.71264 156.9063 2.725841 34611 
58 0 0 0.211538 1.5 0 0.062937 1015 
72 0 0 0 0 0 0 212 
77 1.010471 5.711522 88.9589 216.4667 0 4.733236 44387 
87 0.008693 71.10909 10.21149 30.79528 55.87143 3.055469 28488 
88 0 74.2 7.756098 25.29545 0 0 17873 
99 0 165.5455 32.37333 148.6531 108.7164 2.298517 57741 
130 0.110646 50.57692 26.56566 46.14035 16.3354 3.902077 19681 
136 0.39404 0.606426 2.323077 0.816216 7.74359 0.444118 2874 
158 0 52.78873 22.17751 0 0 4.322953 26525 
187 0 0 47.91509 44.9469 0 5.732506 33808 
191 1.043839 0 63.12791 92.01695 169.6563 4.600847 35260 
195 0.029853 0 6.745501 74.97143 0 2.707946 60707 
196 0.240115 0 32.34071 112.4462 235.7742 2.321054 51918 
201 0.683189 0 29.55814 206.1081 217.8857 4.796226 57156 
205 0.011197 99.45455 23.15344 61.6338 125.0286 4.151803 29390 
207 0.302995 4.96332 15.87037 3.720695 71.41667 2.081781 19669 
1006 1.074778 8.965909 12.32813 9.740741 11.60294 2.72069 5991 
5009 0 1.684906 34.23881 93.63265 148 3.13388 30273 
6004 0.266638 4.278628 11.0205 137 134.3654 2.471525 49354 
6006 0.160913 87.5814 63.83051 0 4.922876 2.850871 25528 
6008 0.434013 0 16.95143 44.94697 15.94892 5.962814 37291 
6009 0.030303 57.2 1.625 33 39.44828 0.594492 24480 
6015 0.341272 90.44231 16.38676 85.50909 142.5152 1.547039 30215 
6016 0.210776 9.032086 3.526096 34.46939 42.225 1.864238 12522 
6021 0.005796 137.3889 2.296193 95.11538 200.5135 1.019934 53929 
 
 
 
 
 
 
 
